



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/62, 1/21, A61K 39/02 // (C12N 1/21, C12R 1:19, C12N 15:62, C12R 1:63)	A1	(11) International Publication Number: WO 98/44130 (43) International Publication Date: 8 October 1998 (08.10.98)
(21) International Application Number: PCT/KR98/00073 (22) International Filing Date: 31 March 1998 (31.03.98) (30) Priority Data: 1997/11950 31 March 1997 (31.03.97) KR 1997/11951 31 March 1997 (31.03.97) KR (71) Applicant (for all designated States except US): DAEWOONG PHARMACEUTICAL CO., LTD. [KR/KR]; 223-23, Sangdaewon-dong, Joongwon-ku, Sungnam, Kyunggi-do 462-120 (KR). (72) Inventors; and (75) Inventors/Applicants (for US only): KIM, Byung-O [KR/KR]; 1108-1601, Samwhan Apartment, Imae-dong, Bundang-ku, Sungnam, Kyunggi-do 463-060 (KR). SHIN, Sung-Seup [KR/KR]; 102-507 Gilhun Apartment, 469-3, Shingok-Ri, Gochon-Myun, Kimpo-gun, Kyunggi-do 415-810 (KR). YU, Young-Hyo [KR/KR]; 733-1201, Daerim Solgoe Apartment, Sanbon-dong, Kunpo, Kyunggi-do 435-040 (KR). PARK, Myung-Hwan [KR/KR]; 91-107, Hyundai Apartment, Apgoojung-dong, Kangnam-ku, Seoul 135-110 (KR). CHOI, Dock-Joon [KR/KR]; 512-508, Hanyang Apartment, 24, Sunae-dong, Bundang-ku, Sungnam,	Kyunggi-do 463-020 (KR). JUNG, Hyung-Jin [KR/KR]; 309-50, 2nd Street, Sungsoo-dong, Sungdong-ku, Seoul 133-120 (KR). (74) Agent: LEE, Han-Young; Daiyun Building, 6th floor, 1688-5, Seocho-dong, Seocho-ku, Seoul 137-070 (KR). (81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. With an indication in relation to deposited biological material furnished under Rule 13bis separately from the description.	
(54) Title: RECOMBINANT MICROORGANISMS EXPRESSING ANTIGENIC PROTEINS OF <i>HELICOBACTER PYLORI</i> (57) Abstract <p>The present invention relates to chimeric proteins consisting of antigenic proteins of <i>Helicobacter pylori</i> and A2 and B subunits of <i>Vibrio cholerae</i> toxin, more specifically, to recombinant DNAs coding for antigenic proteins <i>Helicobacter pylori</i> and A2 and B subunits of <i>Vibrio cholerae</i> toxin, recombinant expression vectors containing the genes, a process for preparing the chimeric proteins employing the recombinant microorganisms transformed with the said expression vectors, and preventive and therapeutic vaccines comprising the chimeric proteins for <i>Helicobacter pylori</i>-associated diseases. The recombinant DNAs which are designed for convenient expression and gene manipulation, can express chimeric proteins having excellent immunogenicity to <i>H. pylori</i>, which are stable in stomach, and penetrate mucous membrane of intestines easily, finally to stimulate production of sIgA. Accordingly, the chimeric proteins expressed from the recombinant DNAs may be used as an active ingredient of the diagnostic kit for <i>H. pylori</i> infection and preventive or therapeutic vaccine for <i>H. pylori</i>-associated diseases, and may be used in the production of anti-<i>H. pylori</i> antibody.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TC	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

RECOMBINANT MICROORGANISMS EXPRESSING ANTIGENIC
PROTEINS OF Helicobacter pylori

BACKGROUND OF THE INVENTION

5

Field of the Invention

The present invention relates to chimeric proteins consisting of antigenic proteins of Helicobacter pylori and
10 A2 and B subunits of Vibrio cholerae toxin, more specifically, to recombinant DNAs coding for antigenic proteins of Helicobacter pylori and A2 and B subunits of Vibrio cholerae toxin, recombinant expression vectors containing the genes, a process for preparing the chimeric proteins employing the
15 recombinant microorganisms transformed with the said expression vectors, and preventive and therapeutic vaccines comprising the chimeric proteins for Helicobacter pylori-associated diseases.

20 Description of the Prior Art

Although gastritis-associated diseases such as gastritis, gastric ulcer and duodenal ulcer are caused by various etiological factors, they are mainly caused by
25 Helicobacter pylori (hereinafter, referred to as 'H. pylori') colonizing in the junctional region of epithelial cells of stomach mucous membrane. It has been reported that 90% or more of Asians and 60% or more of Europeans are infected with H. pylori though there are local differences. Also, it has
30 been known that recurrence of gastritis, gastric ulcer or duodenal ulcer is caused by drug-resistant H. pylori, which may give rise to the occurrence of gastric cancer (see: Timothy, et al., ASM News, 61:21(1995)).

So far, a variety of chemical therapeutic agents such
35 as antibiotics and anti-ulcer agents have been used, in order to treat the gastritis-associated diseases caused by H. pylori. However, these drugs have revealed some drawbacks

as followings: limitation in penetrating the mucous membrane of intestines, emergence of drug-resistant microorganisms, occurrence of reinfection and untoward effects of the drugs. Under the circumstances, there are strong reasons for exploring and developing alternative drugs for the control of H. pylori employing new therapeutic approach, e.g., immunological therapy which can substitute for chemical therapy.

Recently, in order to solve the said problems, studies on the development of vaccines to H. pylori have been carried out. As a result, diagnostic agents of H. pylori infection and preventive vaccines for H. pylori-associated diseases have been developed, employing genes coding for antigenic determinants of H. pylori, e.g., urease gene(see: Timothy, et al., Infection and Immunity, 59:1264(1991)), flagella gene(see: Leying, et al., Molecular Microbiology, 6:2863(1992)), adhesin gene(see: Evans, et al., Journal of Bacteriology, 175:674(1993)), superoxide dismutase gene(see: Christiane, et al., Infection and Immunity, 61:5315(1993)), catalase gene and vacuolating cytotoxin gene(see: Timothy, et al., Infection and Immunity, 58:603(1990)), some of which have been tested in preclinical phase.

However, they have not been manufactured up to now, owing to the following disadvantages: a vaccine employing an urease gene has poor immunogenicity; a vaccine employing a vacuolating cytotoxin gene may have toxicity of cytotoxin itself, though it provides excellent immunogenicity; a vaccine employing a non-toxic variant gene of the vacuolating cytotoxin gene does not have effects on all over the strains of H. pylori, since the non-toxic variant gene does not appear in all H. pylori; and, a vaccine employing adhesin gene, despite its excellent immunogenicity, does not have good efficacy, since it does not stimulate production of secretory IgA("sIgA").

In general, H. pylori is controlled by sIgA not by serum IgG, since it colonizes in the junctional region of epithelial

cells of stomach mucous membrane. However, since the aforesaid vaccines cannot penetrate the mucous membrane of intestines easily, they are not able to stimulate mucosal immune system, which, in turn, results in decreased production of sIgA. Thus, serious problems have occurred that immunological effects of the vaccines against H. pylori decrease and the vaccines are easily denaturated by gastric acid(pH 1-2) to provide poor activities.

10 SUMMARY OF THE INVENTION

Since vaccines employing H. pylori gene alone have the said various disadvantages, the present inventors have made an effort to prepare a chimeric protein fused with a protein which can penetrate mucous membrane of intestines easily and stimulate mucosal immune system to produce sIgA, as a fusion partner, for the purpose of using the chimeric protein as a potential vaccine for H. pylori.

Thus, the present inventors, first, prepared chimeric proteins expressed from recombinant DNAs which contain genes coding for antigenic determinants of H. pylori and A2 and B subunit genes of Vibrio cholerae toxin. Also, they discovered that the chimeric proteins successfully solve the problems of the conventional vaccines and can be used as effective vaccines for H. pylori, based on their excellent immunogenicity for H. pylori, stability under stomach environment, and penetrating property through intestinal membrane to stimulate sIgA production.

30 The first object of the invention is, therefore, to provide a series of DNA sequences prepared by ligating antigenic determinant coding genes of H. pylori and A2 and B subunit genes of Vibrio cholerae toxin, and amino acid sequences translated therefrom.

35 The second object of the invention is to provide expression vectors comprising the said DNA sequences and recombinant microorganisms transformed therewith.

The third object of the invention is to provide a process for preparing chimeric proteins consisting antigen proteins of H. pylori and A2 and B subunits of Vibrio cholerae toxin from the said microorganisms.

5 The fourth object of the invention is to provide preventive and therapeutic vaccines for H. pylori-associated diseases employing the chimeric proteins prepared above.

BRIEF DESCRIPTION OF THE DRAWINGS

10

The above and the other objects and features of the present invention will become apparent from the following descriptions given in conjunction with the accompanying drawings, in which:

15

Figure 1 shows a DNA sequence of a fusion gene prepared by ligating ureB gene of H. pylori and A2 and B subunit genes of Vibrio cholerae toxin.

20

Figure 2 shows an amino acid sequence translated from the DNA sequence of Figure 1.

Figure 3 shows a DNA sequence of a fusion gene prepared by ligating cagA gene of H. pylori and A2 and B subunit genes of Vibrio cholerae toxin.

25

Figure 4 shows an amino acid sequence translated from the DNA sequence of Figure 3.

Figure 5 is a schematic diagram showing construction strategy of an expression vector for UreB/CTXA2B, pHU044.

30

Figure 6 is a schematic diagram showing construction strategy of an expression vector for CagA/CTXA2B, pHC033.

Figure 7 is a photograph showing 15% SDS-PAGE pattern of whole cell lysate of E. coli transformed with pHU044 expression vector.

35

Figure 8 is a photograph showing 15% SDS-PAGE pattern of whole cell lysate of E. coli transformed with pHC033 expression vector.

Figure 9 is a chromatogram showing comparison of serum IgG production of mice immunized with UreB/CTXA2B chimeric protein and UreB, respectively.

5 Figure 10 is a chromatogram showing comparison of secretory IgA production of mice immunized with UreB/CTXA2B chimeric protein and UreB, respectively.

10 Figure 11 is a chromatogram showing comparison of serum IgG production of mice immunized with CagA/CTXA2B chimeric protein and CagA, respectively.

15 Figure 12 is a chromatogram showing comparison of secretory IgG production of mice immunized with CagA/CTXA2B chimeric protein and CagA, respectively.

DETAILED DESCRIPTION OF THE INVENTION

20 The present inventors first gave an attention to the following characteristics of a toxin gene of Vibrio cholerae in the course of searching for a fusion partner of H. pylori gene: A gene of Vibrio cholerae toxin consists of genes coding for three subunits of A1, A2 and B. A1 subunit has a toxic
25 activity of the toxin, and A2 and B subunits bind to host cell to stimulate production of sIgA and guarantee stability of the protein under a surrounding environment. Also, vaccines employing A2 and B subunit genes of Vibrio cholerae toxin can be applied to human body, due to their tolerable
30 characteristics, while various vaccines employing intact cholera toxin gene as a fusion partner, owing to toxic property of A1 subunit, can not be used directly for human body. Further, studies on a vaccine employing A2 and B subunits of cholera toxin as a fusion partner, have revealed
35 that production of sIgA and serum IgG is stimulated when a chimeric protein prepared by ligating A2 and B subunit genes of cholera toxin with adhesin gene of Streptococcus mutans is orally administrated(see: Hajishengallis, et al., The

Journal of Immunology, 154:4322(1995)).

Grounded on the afore-mentioned knowledges, the present inventors prepared chimeric proteins employing A2 and B subunit genes of Vibrio cholerae toxin and antigenic
5 determinant coding genes of H. pylori whose products have excellent immunogenicity, in order to stimulate production of antibody to H. pylori. The antigenic determinant coding genes of H. pylori include ureB, cagA, alpA, alpB, fliQ, babA1, babA2, ureC, ureD, ureA, sodB, ureI, ureE, ureF, ureG, ureH,
10 flaA, flaB, catA, vacA, and babB.

First, the antigenic determinant coding genes of H. pylori and A2 and B subunit genes of Vibrio cholerae toxin were prepared by employing polymerase chain reaction(PCR) technique, respectively. Then, each gene was cleaved with
15 EcoRI and said two genes were ligated with T₄ DNA ligase. The fusion genes thus prepared were cleaved with restriction enzymes, and inserted into plasmid vectors to prepare respective recombinant expression vectors. Then, E. coli was transformed with each of expression vector, the
20 recombinant E. coli was cultured, and chimeric proteins of antigenic proteins of H. pylori and A2 and B subunits of Vibrio cholerae toxin were obtained.

The antibody production rates and their effects as potential vaccines against H. pylori of the said chimeric
25 proteins were examined. As a result, it was found that use of the said chimeric proteins permit to solve the problem of the conventional vaccines using the antigenic proteins, i.e., no stimulation of sIgA production, and mice immunized with the said chimeric proteins produced considerable amount
30 of sIgA compared to mice administered with the antigenic protein alone. Also, it was revealed that mice immunized with the chimeric proteins showed prevention rate against infection with H. pylori of 75% while control group and mice immunized with only antigenic protein showed lower than 55%
35 of prevention rate, respectively, which clearly demonstrates that the chimeric proteins may be used as active ingredients of vaccines for prevention and treatment of H. pylori-associated diseases, diagnostic kits for H. pylori infection,

and used in the production of anti-H. pylori antibody.

The chimeric proteins of the invention induce mucosal immune response to bring about infiltration of IgA antibodies and/or lymphocytes into gastric mucosa. Thus, prevention of
5 H. pylori infection or removal of H. pylori already infected can be accomplished. Accordingly, the chimeric proteins can be administered for the prevention of H. pylori infection of normal people or for the removal of H. pylori and the treatment of H. pylori-associated diseases of H. pylori-
10 infected patients.

The chimeric proteins of the invention can be manufactured in a medicament for the conventional oral administration such as solutions, tablets, capsules and granules, and administered orally.

15 The said medicament for the oral administration can be manufactured by formulating them with pharmaceutically acceptable buffering agents such as sodium bicarbonate, potassium bicarbonate and sodium phosphate to protect the chimeric proteins stably by increasing pH of gastric juice
20 or neutralizing the gastric juice, and manufactured by formulating them with various pharmaceutically acceptable carriers such as stabilizers and sweeteners.

Also, the medicament can be mixed with other antibiotics, etc. for effective prevention of H. pylori infection and
25 removal of H. pylori, and with various anti-ulcer agents for shortening of period required for the treatment of gastritis, gastric ulcer or duodenal ulcer.

In general, the chimeric proteins, in case of an adult of 60kg body weight, may be administered preferably in one
30 dose of 10 μ g to 1,000mg per day, and the dosage may be changed by the conventionally skilled in the art. If necessary, re-administration may be performed at 1-week or 2-week intervals to induce a booster reaction, and a booster dose may be the same as or lower than that during the primary
35 administration.

As a result of oral administration of the chimeric proteins into 10 mice, it was found that all of the proteins have LD₅₀ of 4g/kg or more, which shows that the chimeric proteins are sufficiently safe in the range of effective

dose.

The present invention further provides preventive and therapeutic vaccines for H. pylori-associated diseases which
5 comprise the chimeric proteins' functional equivalents.

In describing the amino acid sequence and the nucleotide sequence of the present invention, the term 'functional equivalents' is employed to mean all proteins substituted by the combinations such as Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and, Phe, Tyr among the
10 amino acid sequences of the chimeric protein, and all genes comprising nucleotide sequences coding for all the said combinations among the nucleotide sequences of the fusion gene, respectively.

15

The present invention is further illustrated in the following examples, which should not be taken to limit the scope of the invention.

20 Example 1: Isolation of chromosomal DNA from H. pylori

H. pylori 11637 RPH 13487(ATCC 43504) was cultured in the BHI (brain heart infusion) liquid medium (consisting of 10mg/ml vancomycin, 5mg/ml trimetofrim and 4mg/ml
25 amphotericin B) containing 5% horse serum, and incubated for 72 hours under an environment of 10%(v/v) CO₂. Then, chromosomal DNA was isolated from the cultured cells by the conventional method in the art.

30 Example 2: Synthesis of oligonucleotides for amplification of antigenic determinant coding genes

Example 2-1: Synthesis of oligonucleotides for ureB gene amplification

35

Two oligonucleotides of 37-mer and 30-mer as followings, were synthesized to amplify ureB gene of H. pylori by PCR technique described in Example 3 below:

5'-CCGTG GATGA AAAAG ATTAG CAGAA AAGAA TATGC TT-3'
5'-AGAAT TCTCA CTTTA TTGGC TGTT TAGAG-3'

5 In an analogous manner, two oligonucleotides of 28-mer and 27-mer as followings, were synthesized to amplify A2 and B subunit genes of Vibrio cholerae toxin:

5'-AGAAT TCGAA GAGCC GTGGA TTCAT CAT-3'
10 5'-ACTGC AGCAC ATAAT ACGCA CTAAG GA-3'

In this connection, the oligonucleotides were synthesized employing an automatic nucleotide synthesizer (Pharmacia-LKB Biotechnology, Uppsala, Sweden).

15 The oligonucleotides thus prepared were reacted with TTD (thiophenol/triethylamine/dioxane=1/2/2, v/v/v) solution in a silica matrix, washed with methanol and ethanol sufficiently, and treated with strong ammonia water to separate the synthesized oligonucleotides from the silica
20 matrix. To the oligonucleotide solutions thus obtained was further added strong ammonia water. Then, the solutions were left to stand at 50°C for 12 hours, and concentrated under a reduced pressure with gas removal to reach a final volume of 0.5ml. And then, using the oligonucleotides thus
25 concentrated, primary purification was carried out with acetonitrile/triethylamine buffer employing a SEP-PAK cartridge (Waters Inc., USA), and electrophoresis was performed using 15% polyacrylamide gel (in TE-borate, pH 8.3).

After electrophoresis, oligonucleotides were visualized
30 under shortwave ultraviolet rays, and only the gel fragments corresponding to the oligonucleotides were cleaved. Then, oligonucleotides were electroeluted from the gel fragments, while remaining salts with acetonitrile/triethylamine buffer employing SEP-PAK cartridge connected with a syringe
35 to purify each oligonucleotide. Oligonucleotides thus purified were labelled with γ -[³²P]-ATP employing T₄ polynucleotide kinase (New England Biolabs, #201S, USA) and

the nucleotide sequences were determined by Maxam and Gilbert's nucleotide sequencing method(see: Maxam, A.M. & Gilbert, W., Proc. Natl. Acad. Sci., USA, 74:560-564(1977)).

5 Example 2-2: Synthesis of oligonucleotides for cagA gene amplification

Two oligonucleotides of 37-mer and 30-mer as followings, were synthesized to amplify cagA gene of H. pylori in an analogous manner as in Example 2-1:

5'-CCGTG GATGA CTAAC GAAAC CATTG ACCAA CAACC AC-3'
5'-AGAAT TCTTA AGATT TTTGG AAACC ACCTT-3'

15 Example 2-3: Synthesis of oligonucleotides for alpA gene amplification

Two oligonucleotides of 23-mer and 21-mer as followings, were synthesized to amplify alpA gene of H. pylori in an analogous manner as in Example 2-1:

5'-CCGTG GATGA TAAAA AAGAA TAG-3'
5'-GAATT CTTAG AATGA ATACC C-3'

25 Example 2-4: Synthesis of oligonucleotides for alpB gene amplification

Two oligonucleotides of 25-mer and 21-mer as followings, were synthesized to amplify alpB gene of H. pylori in an analogous manner as in Example 2-1:

5'-CCGTG GATGA CACAA TCTCA AAAAG-3'
5'-GAATT CTTAG AAGGC GTAGC C-3'

35 Example 2-5: Synthesis of oligonucleotides for fliQ gene amplification

Two oligonucleotides of 24-mer and 21-mer as followings, were synthesized to amplify fliQ gene of H. pylori in an analogous manner as in Example 2-1:

5 5'-CCGTG GATGG AATCA CAACT CATG-3'
 5'-GAATT CGCCT ATGAT TTTGG G-3'

Example 2-6: Synthesis of oligonucleotides for babA1 gene amplification

10

Two oligonucleotides of 21-mer and 21-mer as followings, were synthesized to amplify babA1 gene of H. pylori in an analogous manner as in Example 2-1:

15 5'-CCGTG GATGG TAACA AACAC C-3'
 5'-GAATT CTTAG TAAGC GAACA C-3'

Example 2-7: Synthesis of oligonucleotides for babA2 gene amplification

20

Two oligonucleotides of 22-mer and 21-mer as followings, were synthesized to amplify babA2 gene of H. pylori in an analogous manner as in Example 2-1:

25 5'-CCGTG GATGA AAAAA CACAT CC-3'
 5'-GAATT CTAA TAAGC GAACA C-3'

Example 2-8: Synthesis of oligonucleotides for ureC gene amplification

30

Two oligonucleotides of 21-mer and 23-mer as followings, were synthesized to amplify ureC gene of H. pylori in an analogous manner as in Example 2-1:

35 5'-CCGTG GATGA AAATT TTTGG G-3'
 5'-GAATT CTTAG CACAA ATGCC CTT-3'

Example 2-9: Synthesis of oligonucleotides for ureD gene amplification

Two oligonucleotides of 24-mer and 23-mer as followings,
5 were synthesized to amplify ureD gene of H. pylori in an analogous manner as in Example 2-1:

5'-CCGTG GGTGC TAAAA ACCAC TAAA-3'

5'-GAATT CTCAT GACAT CAGCG AAG-3'

10

Example 2-10: Synthesis of oligonucleotides for ureA gene amplification

Two oligonucleotides of 25-mer and 22-mer as followings,
15 were synthesized to amplify ureA gene of H. pylori in an analogous manner as in Example 2-1:

5'-CCGTG GATGA AACTC ACCCC AAAAG-3'

5'-GAATT CTTAC TCCTT AATTG TT-3'

20

Example 2-11: Synthesis of oligonucleotides for sodB gene amplification

Two oligonucleotides of 24-mer and 25-mer as followings,
25 were synthesized to amplify sodB gene of H. pylori in an analogous manner as in Example 2-1:

5'-CCGTG GATGT TTACA TTACG AGAG-3'

5'-GAATT CTCAT TCAAG CTTTT TATGC-3'

30

Example 2-12: Synthesis of oligonucleotides for ureI gene amplification

Two oligonucleotides of 26-mer and 24-mer as followings,
35 were synthesized to amplify ureI gene of H. pylori in an analogous manner as in Example 2-1:

10

Two oligonucleotides of 22-mer and 21-mer as followings, were synthesized to amplify ureE gene of H. pylori in an analogous manner as in Example 2-1:

5' -CCGTG GATGA TCATA GAGCG TT-3'
5' -GAATT CCTAT TTCAT GACCA C-3'

20

Two oligonucleotides of 25-mer and 23-mer as followings, were synthesized to amplify ureF gene of H. pylori in an analogous manner as in Example 2-1:

5' -CCGTG GATGG ATAAA GGAAA AAGCG-3'
5' -GAATT CTCAA GACAT ATAAA GGC-3'

30

Two oligonucleotides of 25-mer and 25-mer as followings, were synthesized to amplify ureG gene of H. pylori in an analogous manner as in Example 2-1:

5'-CCGTG GATGG TAAAA ATTGG AGTTT-3'
5'-GAATT CTCAA TCTTC CAATA AAGCG-3'

35

Two oligonucleotides of 22-mer and 20-mer as followings,

were synthesized to amplify ureH gene of H. pylori in an analogous manner as in Example 2-1:

5' CCGTG GATGA ACACT TACGC TC-3'
5' GAATT CTTAA ACCTT TGGCG-3'

Example 2-17: Synthesis of oligonucleotides for flaA gene amplification

Two oligonucleotides of 21-mer and 20-mer as followings, were synthesized to amplify flaA gene of H. pylori in an analogous manner as in Example 2-1:

5'-CCGTG GATGG CTTTT CAGGT C-3'
5'-GAATT CCTAA GTTAA AAGCC-3'

Example 2-18: Synthesis of oligonucleotides for flaB gene amplification

Two oligonucleotides of 23-mer and 21-mer as followings, were synthesized to amplify flaB gene of H. pylori in an analogous manner as in Example 2-1:

5'-CCGTG GATGA GTTTT AGGAT AAA-3'
5'-GAATT CTTAT TGTA AAGCC T-3'

Example 2-19: Synthesis of oligonucleotides for catA gene amplification

Two oligonucleotides of 24-mer and 27-mer as followings, were synthesized to amplify catA gene of H. pylori in an analogous manner as in Example 2-1:

5'-CCGTG GATGG TTAAT AAAGA TGTG-3'
5'-GAATT CTTAC TTTT CTTT TTGTG TG-3'

Example 2-20: Synthesis of oligonucleotides for vacA gene

amplification

Two oligonucleotides of 24-mer and 26-mer as followings,
were synthesized to amplify vacA gene of H. pylori in an
5 analogous manner as in Example 2-1:

5'-CCGTG GGCCT TTTT ACAAC CGTG-3'

5'-GAATT CTTAG AAAC ATACC TCAGG C-3'

10 Example 2-21: Synthesis of oligonucleotides for babB gene
amplification

Two oligonucleotides of 23-mer and 21-mer as followings,
were synthesized to amplify babB gene of H. pylori in an
15 analogous manner as in Example 2-1:

5'-CCGTG GATGA AAAAA AACCC TTT-3'

5'-GAATT CCTAG TAAGC GAACA C-3'

20 Example 3: Amplification of antigenic determinant genes

Example 3-1: Amplification of ureB gene and A2/B subunit genes
of Vibrio cholerae

25 To the solution containing template DNA (10ng), 10 μ l of
10x Taq polymerase buffer (10mM Tris-HCl (pH 8.3) containing
500mM KCl, 15mM MgCl₂ and 0.1% (v/v) gelatin), 10 μ l of dNTP's
mixture (containing an equimolar concentration of 1.25mM dGTP,
dATP, dTTP and dCTP), 2 μ g of each primer (oligonucleotides
30 synthesized in Example 2-1) and 0.5 μ l of Ampli Taq DNA
polymerase (Perkin-Elmer Cetus, USA), was added distilled
water to be a final volume of 100 μ l. In order to prevent
evaporation of the solution, 50 μ l of mineral oil was added
to the solution. In case of amplification of ureB gene of
35 H. pylori, chromosomal DNA of H. pylori isolated in Example
1 was used as a template DNA, and oligonucleotides synthesized

in Example 2-1, i.e., 37-mer and 30-mer, were used as primers; and, in case of amplification of A2 and B subunit genes of Vibrio cholerae toxin, chromosomal DNA of Vibrio cholerae was used as a template DNA, and oligonucleotides synthesized in Example 2-1, i.e., 28-mer and 27-mer, were used as primers.

Denaturation(95°C, 1 minute), annealing(55°C, 1 minute), and extension(72°C, 2 minute) were carried out for 30 cycles in a serial manner, using Thermal Cycler TM(Cetus/Perkin-Elmer, USA), and final reaction was carried out at 72°C for 10 minutes. And then, in order to remove polymerase, the equal volume of phenol/chloroform mixture(1:1(v/v)) was added to the reaction mixture, mixed well, and subsequently centrifuged. The supernatant thus obtained was transferred to a fresh tube. Then, 1/10 volume of 3M sodium acetate and 2 volume of 100% ethanol was added to the supernatant, mixed and centrifuged to obtain double-stranded nucleic acid. The nucleic acid was dissolved in 20μl of TE buffer for later use.

20 Example 3-2: Amplification of cagA gene and A2/B subunit genes of Vibrio cholerae

To the solution containing template DNA(10ng), 10μl of 10x Taq polymerase buffer(10mM Tris-HCl(pH 8.3) containing 25 500mM KCl, 15mM MgCl₂ and 0.1%(v/v) gelatin), 10μl of dNTP's mixture(containing an equimolar concentration of 1.25mM dGTP, dATP, dTTP and dCTP), 2μg of each primer(oligonucleotides synthesized in Example 2-2) and 0.5μl of Ampli Taq DNA polymerase(Perkin-Elmer Cetus, USA), was added distilled 30 water to be a final volume of 100μl. In order to prevent evaporation of the solution, 50μl of mineral oil was added to the solution. In case of amplification of cagA gene of H. pylori, chromosomal DNA of H. pylori isolated in Example 1 was used as a template DNA, and oligonucleotides synthesized 35 in Example 2-2, i.e., 37-mer and 30-mer, were used as primers; and, in case of amplification of A2 and B subunit genes of

Vibrio cholerae toxin, chromosomal DNA of Vibrio cholerae was used as a template DNA, and oligonucleotides synthesized in Example 2-1, i.e., 28-mer and 27-mer, were used as primers.

Denaturation (95°C, 1 minute), annealing (55°C, 1 minute),
5 and extension (72°C, 2 minute) were carried out for 30 cycles
in a serial manner, using Thermal Cycler
TM (Cetus/Perkin-Elmer, USA), and final reaction was carried
out at 72°C for 10 minutes. And then, in order to remove
polymerase, the equal volume of phenol/chloroform
10 mixture (1:1 (v/v)) was added to the reaction mixture, mixed
well, and subsequently centrifuged. The supernatant thus
obtained was transferred to a fresh tube. Then, 1/10 volume
of 3M sodium acetate and 2 volume of 100% ethanol was added
to the supernatant, mixed and centrifuged to obtain
15 double-stranded nucleic acid. The nucleic acid was
dissolved in 20 µl of TE buffer for later use.

Example 3-3: Amplification of alpA gene and A2/B subunit genes
of Vibrio cholerae

20

alpA gene and A2/B subunit gene of Vibrio cholerae were
amplified in an analogous manner as in Example 3-1, with the
exceptions that: chromosomal DNA of H. pylori isolated in
Example 1 was employed as template DNA, and oligonucleotides
25 of 23-mer and 21-mer synthesized in Example 2-3 were employed
as primer.

Example 3-4: Amplification of alpB gene and A2/B subunit
genes of Vibrio cholerae

30

alpB gene and A2/B subunit gene of Vibrio cholerae were
amplified in an analogous manner as in Example 3-1, with the
exceptions that: chromosomal DNA of H. pylori isolated in
Example 1 was employed as template DNA, and oligonucleotides
35 of 25-mer and 21-mer synthesized in Example 2-4 were employed
as primer.

Example 3-5: Amplification of fliQ gene and A2/B subunit genes of *Vibrio cholerae*

5 fliQ gene and A2/B subunit gene of *Vibrio cholerae* were amplified in an analogous manner as in Example 3-1, with the exceptions that: chromosomal DNA of *H. pylori* isolated in Example 1 was employed as template DNA, and oligonucleotides of 24-mer and 21-mer synthesized in Example 2-5 were employed
10 as primer.

Example 3-6: Amplification of babA1 gene and A2/B subunit genes of *Vibrio cholerae*

15 babA1 gene and A2/B subunit gene of *Vibrio cholerae* were amplified in an analogous manner as in Example 3-1, with the exceptions that: chromosomal DNA of *H. pylori* isolated in Example 1 was employed as template DNA, and oligonucleotides of 21-mer and 21-mer synthesized in Example 2-6 were employed
20 as primer.

Example 3-7: Amplification of babA2 gene and A2/B subunit genes of *Vibrio cholerae*

25 babA2 gene and A2/B subunit gene of *Vibrio cholerae* were amplified in an analogous manner as in Example 3-1, with the exceptions that: chromosomal DNA of *H. pylori* isolated in Example 1 was employed as template DNA, and oligonucleotides of 22-mer and 21-mer synthesized in Example 2-7 were employed
30 as primer.

Example 3-8: Amplification of ureC gene and A2/B subunit genes of *Vibrio cholerae*

35 ureC gene and A2/B subunit gene of *Vibrio cholerae* were amplified in an analogous manner as in Example 3-1, with the exceptions that: chromosomal DNA of *H. pylori* isolated in

Example 1 was employed as template DNA, and oligonucleotides of 21-mer and 23-mer synthesized in Example 2-8 were employed as primer.

5 Example 3-9: Amplification of ureD gene and A2/B subunit genes of *Vibrio cholerae*

ureD gene and A2/B subunit gene of *Vibrio cholerae* were amplified in an analogous manner as in Example 3-1, with the
10 exceptions that: chromosomal DNA of *H. pylori* isolated in Example 1 was employed as template DNA, and oligonucleotides of 24-mer and 23-mer synthesized in Example 2-9 were employed as primer.

15 Example 3-10: Amplification of ureA gene and A2/B subunit genes of *Vibrio cholerae*

ureA gene and A2/B subunit gene of *Vibrio cholerae* were amplified in an analogous manner as in Example 3-1, with the
20 exceptions that: chromosomal DNA of *H. pylori* isolated in Example 1 was employed as template DNA, and oligonucleotides of 25-mer and 22-mer synthesized in Example 2-10 were employed as primer.

25 Example 3-11: Amplification of sodB gene and A2/B subunit genes of *Vibrio cholerae*

sodB gene and A2/B subunit gene of *Vibrio cholerae* were amplified in an analogous manner as in Example 3-1, with the
30 exceptions that: chromosomal DNA of *H. pylori* isolated in Example 1 was employed as template DNA, and oligonucleotides of 24-mer and 25-mer synthesized in Example 2-11 were employed as primer.

35 Example 3-12: Amplification of ureI gene and A2/B subunit genes of *Vibrio cholerae*

ureI gene and A2/B subunit gene of Vibrio cholerae were amplified in an analogous manner as in Example 3-1, with the exceptions that: chromosomal DNA of H. pylori isolated in Example 1 was employed as template DNA, and oligonucleotides
5 of 26-mer and 24-mer synthesized in Example 2-12 were employed as primer.

Example 3-13: Amplification of ureE gene and A2/B subunit genes of Vibrio cholerae

10

ureE gene and A2/B subunit gene of Vibrio cholerae were amplified in an analogous manner as in Example 3-1, with the exceptions that: chromosomal DNA of H. pylori isolated in Example 1 was employed as template DNA, and oligonucleotides
15 of 22-mer and 21-mer synthesized in Example 2-13 were employed as primer.

Example 3-14: Amplification of ureF gene and A2/B subunit genes of Vibrio cholerae

20

ureF gene and A2/B subunit gene of Vibrio cholerae were amplified in an analogous manner as in Example 3-1, with the exceptions that: chromosomal DNA of H. pylori isolated in Example 1 was employed as template DNA, and oligonucleotides
25 of 25-mer and 23-mer synthesized in Example 2-14 were employed as primer.

Example 3-15: Amplification of ureG gene and A2/B subunit genes of Vibrio cholerae

30

ureG gene and A2/B subunit gene of Vibrio cholerae were amplified in an analogous manner as in Example 3-1, with the exceptions that: chromosomal DNA of H. pylori isolated in Example 1 was employed as template DNA, and oligonucleotides
35 of 25-mer and 25-mer synthesized in Example 2-15 were employed as primer.

Example 3-16: Amplification of ureH gene and A2/B subunit genes of *Vibrio cholerae*

ureH gene and A2/B subunit gene of *Vibrio cholerae* were amplified in an analogous manner as in Example 3-1, with the exceptions that: chromosomal DNA of *H. pylori* isolated in Example 1 was employed as template DNA, and oligonucleotides of 22-mer and 20-mer synthesized in Example 2-16 were employed as primer.

10

Example 3-17: Amplification of flaA gene and A2/B subunit genes of *Vibrio cholerae*

flaA gene and A2/B subunit gene of *Vibrio cholerae* were amplified in an analogous manner as in Example 3-1, with the exceptions that: chromosomal DNA of *H. pylori* isolated in Example 1 was employed as template DNA, and oligonucleotides of 21-mer and 20-mer synthesized in Example 2-17 were employed as primer.

20

Example 3-18: Amplification of flaB gene and A2/B subunit genes of *Vibrio cholerae*

flaB gene and A2/B subunit gene of *Vibrio cholerae* were amplified in an analogous manner as in Example 3-1, with the exceptions that: chromosomal DNA of *H. pylori* isolated in Example 1 was employed as template DNA, and oligonucleotides of 23-mer and 21-mer synthesized in Example 2-18 were employed as primer.

30

Example 3-19: Amplification of catA gene and A2/B subunit genes of *Vibrio cholerae*

catA gene and A2/B subunit gene of *Vibrio cholerae* were amplified in an analogous manner as in Example 3-1, with the exceptions that: chromosomal DNA of *H. pylori* isolated in Example 1 was employed as template DNA, and oligonucleotides

35

of 24-mer and 27-mer synthesized in Example 2-19 were employed as primer.

5 Example 3-20: Amplification of vacA gene and A2/B subunit genes of Vibrio cholerae

vacA gene and A2/B subunit gene of Vibrio cholerae were amplified in an analogous manner as in Example 3-1, with the exceptions that: chromosomal DNA of H. pylori isolated in
10 Example 1 was employed as template DNA, and oligonucleotides of 24-mer and 26-mer synthesized in Example 2-20 were employed as primer.

15 Example 3-21: Amplification of babB gene and A2/B subunit genes of Vibrio cholerae

babB gene and A2/B subunit gene of Vibrio cholerae were amplified in an analogous manner as in Example 3-1, with the exceptions that: chromosomal DNA of H. pylori isolated in
20 Example 1 was employed as template DNA, and oligonucleotides of 23-mer and 21-mer synthesized in Example 2-21 were employed as primer.

25 Example 4: Construction of expression vectors expressing chimeric proteins

Example 4-1: Construction of an expression vector, pHU044

The ureB gene of H. pylori and the A2 and B subunit genes
30 of Vibrio cholerae toxin amplified in Example 3-1, respectively, were digested with EcoRI, respectively. Each of 1 μ g of H. pylori DNA and Vibrio cholerae DNA was mixed. Then, 3 μ l of 10x concentrated solution for fusion(600mM Tris-HCl buffer(pH 7.5) containing 10mM DTT and 100mM MgCl₂),
35 1 μ l of 10mM ATP and 10 unit of T₄ DNA ligase were added to the DNA mixture to reach a final reaction volume of 30 μ l.

and held at 14°C for 16 hours. After 1% agarose gel electrophoresis of the reaction product, a fusion gene of about 2.4kb was obtained and its nucleotide sequence was determined(see: Figure 1). In Figure 1, nucleotide sequence of base position 1 to 1679 corresponds to signal peptide sequence of the ureB, and nucleotide sequence of base position 1680 to 1712 corresponds to signal peptide sequence of the B subunit of Vibrio cholerae toxin. Figure 2 shows an amino acid sequence translated from the DNA sequence of Figure 1.

The fusion gene having the nucleotide sequence thus determined was double-digested with DsaI and PstI, and inserted into pTED plasmid vector double-digested with the said restriction enzymes to prepare a circular plasmid which was designated as 'pHU044'. The said plasmid pTED is 2.95kb plasmid which was created DsaI restriction enzyme recognition site to pTE105, isolated from E. coli JM 101(DW/BT-2042)transformed with pTE105(KCCM-10027). Figure 5 is a schematic diagram showing the construction strategy of pHU044.

Further, treatment of pHU044 with restriction enzyme and 1% agarose gel electrophoresis revealed that: the pHU044 expression vector has unique restriction site for each restriction enzyme; and the fusion gene was correctly inserted.

25

Example 4-2: Construction of an expression vector, pHC033

The cagA gene of H. pylori and the A2 and B subunit genes of Vibrio cholerae toxin amplified in Example 3-2, respectively, were digested with EcoRI, respectively. Each of 1μg of H. pylori DNA and Vibrio cholerae DNA was mixed. Then, 3μl of 10x concentrated solution for fusion(600mM Tris-HCl buffer(pH 7.5) containing 10mM DTT and 100mM MgCl₂), 1μl of 10mM ATP and 10 unit of T₄ DNA ligase were added to the DNA mixture to reach a final reaction volume of 30μl, and held at 14°C for 16 hours. After 1% agarose gel

electrophoresis of the reaction product, a fusion gene of about 4.1kb was obtained and its nucleotide sequence was determined(see: Figure 3). In Figure 3, nucleotide sequence of base position 1 to 3444 corresponds to signal peptide sequence of the cagA, and nucleotide sequence of base position 3445 to 3477 corresponds to signal peptide sequence of the B subunit of Vibrio cholerae toxin. Figure 4 shows an amino acid sequence translated from the DNA sequence of Figure 3.

The fusion gene having the nucleotide sequence thus determined was double-digested with DsaI and PstI, and inserted into pTED plasmid vector double-digested with the said restriction enzymes to prepare a circular plasmid which was designated as 'pHC033'. The said plasmid pTED is 2.95kb plasmid which was created DsaI restriction enzyme recognition site to pTE105 isolated from E. coli JM101(DW/BT-2042) transformed with pTE105(KCCM-10027). Figure 6 is a schematic diagram showing the construction strategy of pHC033.

Further, treatment pHC033 with restriction enzyme and 1% agarose gel electrophoresis revealed that: the pHC033 expression vector has unique restriction site for each restriction enzyme; and the fusion gene was correctly inserted.

Example 4-3: Construction of an expression vector containing alpA gene

The alpA gene of H. pylori and the A2 and B subunit genes of Vibrio cholerae toxin amplified in Example 3-3, respectively, were digested with EcoRI, respectively. Each of 1 μ g of H. pylori DNA and Vibrio cholerae DNA was mixed. Then, 3 μ l of 10x concentrated solution for fusion(600mM Tris-HCl buffer(pH 7.5) containing 10mM DTT and 100mM MgCl₂), 1 μ l of 10mM ATP and 10 unit of T₄ DNA ligase were added to the DNA mixture to reach a final reaction volume of 30 μ l, and held at 14°C for 16 hours. After 1% agarose gel

electrophoresis of the reaction product, a fusion gene of about 2.4kb was obtained and its nucleotide sequence was determined. The fusion gene having the nucleotide sequence thus determined was double-digested with DsaI and PstI, and
5 inserted into pTED plasmid vector double-digested with the said restriction enzymes to prepare an expression vector containing a chimeric gene of alpA gene and A2/B subunit gene of Vibrio cholerae toxin.

10 Example 4-4: Construction of an expression vector containing alpB gene

Expression vector containing a chimeric gene of alpB gene and A2/B subunit gene of Vibrio cholerae toxin was
15 prepared in an analogous manner as in Example 4-3, after sequence determination of the fused gene of alpB gene and A2/B subunit gene of Vibrio cholerae toxin of 2.3kb, with an exception of employing alpB gene of H. pylori amplified in Example 3-4.

20

Example 4-5: Construction of an expression vector containing fliQ gene

Expression vector containing a chimeric gene of fliQ
25 gene and A2/B subunit gene of Vibrio cholerae toxin was prepared in an analogous manner as in Example 4-3, after sequence determination of the fused gene of fliQ gene and A2/B subunit gene of Vibrio cholerae toxin of 0.9kb, with an exception of employing fliQ gene of H. pylori amplified
30 in Example 3-5.

Example 4-6: Construction of an expression vector containing babA1 gene

35 Expression vector containing a chimeric gene of babA1 gene and A2/B subunit gene of Vibrio cholerae toxin was prepared in an analogous manner as in Example 4-3, after

sequence determination of the fused gene of babA1 gene and A2/B subunit gene of Vibrio cholerae toxin of 2.8kb, with an exception of employing babA1 gene of H. pylori amplified in Example 3-6.

5

Example 4-7: Construction of an expression vector containing babA2 gene

Expression vector containing a chimeric gene of babA2
10 gene and A2/B subunit gene of Vibrio cholerae toxin was prepared in an analogous manner as in Example 4-3, after sequence determination of the fused gene of babA2 gene and A2/B subunit gene of Vibrio cholerae toxin of 2.9kb, with an exception of employing babA2 gene of H. pylori amplified
15 in Example 3-7.

Example 4-8: Construction of an expression vector containing ureC gene

20 Expression vector containing a chimeric gene of ureC gene and A2/B subunit gene of Vibrio cholerae toxin was prepared in an analogous manner as in Example 4-3, after sequence determination of the fused gene of ureC gene and A2/B subunit gene of Vibrio cholerae toxin of 2.0kb, with
25 an exception of employing ureC gene of H. pylori amplified in Example 3-8.

Example 4-9: Construction of an expression vector containing ureD gene

30

Expression vector containing a chimeric gene of ureD
gene and A2/B subunit gene of Vibrio cholerae toxin was prepared in an analogous manner as in Example 4-3, after sequence determination of the fused gene of ureD gene and
35 A2/B subunit gene of Vibrio cholerae toxin of 1.1kb, with an exception of employing ureD gene of H. pylori amplified in Example 3-9.

Example 4-10: Construction of an expression vector
containing ureA gene

5 Expression vector containing a chimeric gene of ureA
gene and A2/B subunit gene of Vibrio cholerae toxin was
prepared in an analogous manner as in Example 4-3, after
sequence determination of the fused gene of ureA gene and
A2/B subunit gene of Vibrio cholerae toxin of 1.4kb, with
10 an exception of employing ureA gene of H. pylori amplified
in Example 3-10.

Example 4-11: Construction of an expression vector
containing sodB gene

15 Expression vector containing a chimeric gene of sodB
gene and A2/B subunit gene of Vibrio cholerae toxin was
prepared in an analogous manner as in Example 4-3, after
sequence determination of the fused gene of sodB gene and
20 A2/B subunit gene of Vibrio cholerae toxin of 1.3kb, with
an exception of employing sodB gene of H. pylori amplified
in Example 3-11.

Example 4-12: Construction of an expression vector
containing ureI gene

25 Expression vector containing a chimeric gene of ureI
gene and A2/B subunit gene of Vibrio cholerae toxin was
prepared in an analogous manner as in Example 4-3, after
30 sequence determination of the fused gene of ureI gene and
A2/B subunit gene of Vibrio cholerae toxin of 1.3kb, with
an exception of employing ureI gene of H. pylori amplified
in Example 3-12.

35 Example 4-13: Construction of an expression vector
containing ureE gene

Expression vector containing a chimeric gene of ureE gene and A2/B subunit gene of Vibrio cholerae toxin was prepared in an analogous manner as in Example 4-3, after
5 sequence determination of the fused gene of ureE gene and A2/B subunit gene of Vibrio cholerae toxin of 1.2kb, with an exception of employing ureE gene of H. pylori amplified in Example 3-13.

10 Example 4-14: Construction of an expression vector containing ureF gene

Expression vector containing a chimeric gene of ureF gene and A2/B subunit gene of Vibrio cholerae toxin was
15 prepared in an analogous manner as in Example 4-3, after sequence determination of the fused gene of ureF gene and A2/B subunit gene of Vibrio cholerae toxin of 1.5kb, with an exception of employing ureF gene of H. pylori amplified in Example 3-14.

20

Example 4-15: Construction of an expression vector containing ureG gene

Expression vector containing a chimeric gene of ureG
25 gene and A2/B subunit gene of Vibrio cholerae toxin was prepared in an analogous manner as in Example 4-3, after sequence determination of the fused gene of ureG gene and A2/B subunit gene of Vibrio cholerae toxin of 1.3kb, with an exception of employing ureG gene of H. pylori amplified
30 in Example 3-15.

Example 4-16: Construction of an expression vector containing ureH gene

35 Expression vector containing a chimeric gene of ureH gene and A2/B subunit gene of Vibrio cholerae toxin was prepared in an analogous manner as in Example 4-3, after

sequence determination of the fused gene of ureH gene and A2/B subunit gene of Vibrio cholerae toxin of 1.5kb, with an exception of employing ureH gene of H. pylori amplified in Example 3-16.

5

Example 4-17: Construction of an expression vector containing flaA gene

Expression vector containing a chimeric gene of flaA gene and A2/B subunit gene of Vibrio cholerae toxin was prepared in an analogous manner as in Example 4-3, after sequence determination of the fused gene of flaA gene and A2/B subunit gene of Vibrio cholerae toxin of 2.2kb, with an exception of employing flaA gene of H. pylori amplified in Example 3-17.

15

Example 4-18: Construction of an expression vector containing flaB gene

Expression vector containing a chimeric gene of flaB gene and A2/B subunit gene of Vibrio cholerae toxin was prepared in an analogous manner as in Example 4-3, after sequence determination of the fused gene of flaB gene and A2/B subunit gene of Vibrio cholerae toxin of 2.2kb, with an exception of employing flaB gene of H. pylori amplified in Example 3-18.

25

Example 4-19: Construction of an expression vector containing catA gene

30

Expression vector containing a chimeric gene of catA gene and A2/B subunit gene of Vibrio cholerae toxin was prepared in an analogous manner as in Example 4-3, after sequence determination of the fused gene of catA gene and A2/B subunit gene of Vibrio cholerae toxin of 2.2kb, with an exception of employing catA gene of H. pylori amplified in Example 3-19.

35

Example 4-20: Construction of an expression vector
containing vacA gene

5 Expression vector containing a chimeric gene of vacA
gene and A2/B subunit gene of Vibrio cholerae toxin was
prepared in an analogous manner as in Example 4-3, after
sequence determination of the fused gene of vacA gene and
A2/B subunit gene of Vibrio cholerae toxin of 4.5kb, with
10 an exception of employing vacA gene of H. pylori amplified
in Example 3-20.

Example 4-21: Construction of an expression vector
containing ureF gene

15 Expression vector containing a chimeric gene of babB
gene and A2/B subunit gene of Vibrio cholerae toxin was
prepared in an analogous manner as in Example 4-3, after
sequence determination of the fused gene of babB gene and
20 A2/B subunit gene of Vibrio cholerae toxin of 1.4kb, with
an exception of employing babB gene of H. pylori amplified
in Example 3-21.

Example 5: Preparation of transformants expressing chimeric
25 proteins

Example 5-1: Preparation of a transformant containing pHU044

30 In order to transform host cell with the pHU044
expression vector, E. coli JM101 was first inoculated in
liquid LB medium, cultured at 37°C until absorbance at 600nm
reached to a level of 0.25 to 0.5, and harvested, which was
subsequently washed with 0.1M MgCl₂, and centrifuged. To the
precipitate thus obtained were added solution containing
35 0.1M CaCl₂ and 0.05M MgCl₂, and the pHU044 expression vector
prepared in Example 4-1, and incubated on ice. The cells were
centrifuged again, and dispersed uniformly in the same

solution(see: DNA Cloning Vol. I, A Practical Approach, IRL Press, 1985). In this connection, all solutions and tubes were used after cooling at 0°C.

And then, 0.2ml of the cell suspension thus obtained
5 was added to petri dishes coated with liquid LB media containing 12.5µg/ml of tetracycline, and cultured at 37°C overnight to obtain transformant of E. coli JM101 harboring pHU044. The transformant thus prepared was designated as Escherichia coli DW/HU-044, and deposited with the Korean
10 Culture Center of Microorganisms(KCCM), an international depositary authority located at College of Eng., Yonsei University, Sodaemun-gu, Seoul, Korea, under an accession No. KCCM-10124 on March 12, 1997.

15 Example 5-2: Preparation of a transformant containing pHC033

In order to transform host cell with the pHC033 expression vector, E. coli JM101 was first inoculated in
20 liquid LB medium, cultured at 37°C until absorbance at 600nm reached to a level of 0.25 to 0.5, and harvested, which was subsequently washed with 0.1M MgCl₂, and centrifuged. To the precipitate thus obtained were added solution containing 0.1M CaCl₂ and 0.05M MgCl₂, and the pHC033 expression vector
25 prepared in Example 4-2, and incubated on ice. The cells were centrifuged again, and dispersed uniformly in the same solution(see: DNA Cloning Vol. I, A Practical Approach, IRL press, 1985). In this connection, all solutions and tubes were used after cooling at 0°C.

30 And then, 0.2ml of the cell suspension thus obtained was added to petri dishes coated with liquid LB media containing 12.5µg/ml of tetracycline, and cultured at 37°C overnight to obtain transformant of E. coli JM101 harboring pHC033. The transformant thus prepared was designated as
35 Escherichia coli DW/HC-033, and deposited with the Korean Culture Center of Microorganisms(KCCM), an international depositary authority located at College of Eng., Yonsei

University, Korea, under an accession No. KCCM-10123 on March 12, 1997.

5 Example 5-3: Preparation of a transformant expressing
 alpA-fused gene

 Transformant was prepared in an analogous manner as in
Example 5-1, with an exception of employing the expression
vector containing a fused gene of alpA gene and A2/B subunit
10 gene of Vibrio cholerae toxin which was prepared in Example
4-3.

15 Example 5-4: Preparation of a transformant expressing
 alpB-fused gene

 Transformant was prepared in an analogous manner as in
Example 5-1, with an exception of employing the expression
vector containing a fused gene of alpB gene and A2/B subunit
gene of Vibrio cholerae toxin which was prepared in Example
20 4-4.

Example 5-5: Preparation of a transformant expressing
 fliQ-fused gene

25 Transformant was prepared in an analogous manner as in
Example 5-1, with an exception of employing the expression
vector containing a fused gene of fliQ gene and A2/B subunit
gene of Vibrio cholerae toxin prepared in Example 4-5.

30 Example 5-6: Preparation of a transformant expressing
 babA1-fused gene

35 Transformant was prepared in an analogous manner as in
Example 5-1, with an exception of employing the expression
vector containing a fused gene of babA1 gene and A2/B subunit

gene of Vibrio cholerae toxin prepared in Example 4-6.

Example 5-7: Preparation of a transformant expressing
babA2-fused gene

5

Transformant was prepared in an analogous manner as in
Example 5-1, with an exception of employing the expression
vector containing a fused gene of babA2 gene and A2/B subunit
gene of Vibrio cholerae toxin prepared in Example 4-7.

10

Example 5-8: Preparation of a transformant expressing
ureC-fused gene

Transformant was prepared in an analogous manner as in
15 Example 5-1, with an exception of employing the expression
vector containing a fused gene of ureC gene and A2/B subunit
gene of Vibrio cholerae toxin prepared in Example 4-8.

Example 5-9: Preparation of a transformant expressing
20 ureD-fused gene

Transformant was prepared in an analogous manner as in
Example 5-1, with an exception of employing the expression
vector containing a fused gene of ureD gene and A2/B subunit
25 gene of Vibrio cholerae toxin prepared in Example 4-9.

Example 5-10: Preparation of a transformant expressing
ureA-fused gene

30 Transformant was prepared in an analogous manner as in
Example 5-1, with an exception of employing the expression
vector containing a fused gene of ureA gene and A2/B subunit
gene of Vibrio cholerae toxin prepared in Example 4-10.

35 Example 5-11: Preparation of a transformant expressing
sodB-fused gene

Transformant was prepared in an analogous manner as in Example 5-1, with an exception of employing the expression vector containing a fused gene of sodB gene and A2/B subunit gene of Vibrio cholerae toxin prepared in Example 4-11.

Example 5-12: Preparation of a transformant expressing ureI-fused gene

Transformant was prepared in an analogous manner as in Example 5-1, with an exception of employing the expression vector containing a fused gene of ureI gene and A2/B subunit gene of Vibrio cholerae toxin prepared in Example 4-12.

Example 5-13: Preparation of a transformant expressing ureE-fused gene

Transformant was prepared in an analogous manner as in Example 5-1, with an exception of employing the expression vector containing a fused gene of ureE gene and A2/B subunit gene of Vibrio cholerae toxin prepared in Example 4-13.

Example 5-14: Preparation of a transformant expressing ureF-fused gene

Transformant was prepared in an analogous manner as in Example 5-1, with an exception of employing the expression vector containing a fused gene of ureF gene and A2/B subunit gene of Vibrio cholerae toxin prepared in Example 4-14.

Example 5-15: Preparation of a transformant expressing ureG-fused gene

Transformant was prepared in an analogous manner as in Example 5-1, with an exception of employing the expression vector containing a fused gene of ureG gene and A2/B subunit gene of Vibrio cholerae toxin prepared in Example 4-15.

Example 5-16: Preparation of a transformant expressing
ureH-fused gene

5 Transformant was prepared in an analogous manner as in
Example 5-1, with an exception of employing the expression
vector containing a fused gene of ureH gene and A2/B subunit
gene of Vibrio cholerae toxin prepared in Example 4-16.

10 Example 5-17: Preparation of a transformant expressing
flaA-fused gene

 Transformant was prepared in an analogous manner as in
Example 5-1, with an exception of employing the expression
15 vector containing a fused gene of flaA gene and A2/B subunit
gene of Vibrio cholerae toxin prepared in Example 4-17.

Example 5-18: Preparation of a transformant expressing
flaB-fused gene

20

 Transformant was prepared in an analogous manner as in
Example 5-1, with an exception of employing the expression
vector containing a fused gene of flaB gene and A2/B subunit
gene of Vibrio cholerae toxin prepared in Example 4-18.

25

Example 5-19: Preparation of a transformant expressing
catA-fused gene

 Transformant was prepared in an analogous manner as in
30 Example 5-1, with an exception of employing the expression
vector containing a fused gene of catA gene and A2/B subunit
gene of Vibrio cholerae toxin prepared in Example 4-19.

Example 5-20: Preparation of a transformant expressing
35 vacA-fused gene

 Transformant was prepared in an analogous manner as in

Example 5-1, with an exception of employing the expression vector containing a fused gene of vacA gene and A2/B subunit gene of Vibrio cholerae toxin prepared in Example 4-20.

5 Example 5-21: Preparation of a transformant expressing babB-fused gene

Transformant was prepared in an analogous manner as in Example 5-1, with an exception of employing the expression
10 vector containing a fused gene of babB gene and A2/B subunit gene of Vibrio cholerae toxin prepared in Example 4-21.

Example 6: Expression of chimeric proteins

15 Example 6-1: Expression of a chimeric protein in transformant E. coli DW/HU-044

A transformant E. coli DW/HU-044 was inoculated in about 3ml of a medium which is disclosed in Table 1 below, and
20 overnight cultured at 37°C and 250rpm, and 0.5ml of the culture was inoculated in about 50 ml of the same medium and cultured at 37°C while shaking at 250rpm to reach 1.8 to 2.0 of the absorbance at 600nm. Then, to the culture, was added 0.25ml of IPTG(isopropyl β -D-thiogalactoside) and cultured at 37
25 °C at 250rpm for 24hours to induce recombinant protein, centrifuged to collect cells, suspended in a buffer solution(10mM Tris-HCl(pH 8.0) containing 0.1% Triton X-100, 2mM EDTA and 1mM PMSF) to lyse cells, and electrophoresed on 15% SDS-PAGE(see: Figure 7).

30

35

Table 1: Composition of medium for transformant culture

Composition of medium (per liter)	~ 50ml of medium for expression	~ 3ml of medium for expression
Main medium yeast extract 20g casamino acid 10g MgSO ₄ ·7H ₂ O 0.224g CaCl ₂ ·2H ₂ O 0.01g	44ml	2.7ml
10 X phosphate buffer (100ml) KH ₂ PO ₄ 3g Na ₂ HPO ₄ 4g (NH ₄) ₂ HPO ₄ 2.5g	5ml	0.3ml
25% Glucose	1ml	0.06ml
Tetracycline (12.5µg/ml)	0.1ml	0.006ml

- 5 In Figure 7, lane M shows molecular size-marker, lane 1 shows cell lysate before IPTG induction; lane 2 shows cell lysate of 24hrs cultured cells after IPTG induction; top arrow indicates locus of a chimeric protein containing ureB of *H. pylori* and A2 subunit of *Vibrio cholerae* toxin; and, bottom
- 10 arrow indicates locus of B subunit of *Vibrio cholerae* toxin.

As shown in Figure 7, it was found that the transformed *E. coli* DW/HU-044 successfully expresses a chimeric protein, which is designated as 'UreB/CTXA2B'.

- 15 Example 6-2: Expression of a chimeric protein in transformant *E. coli* DW/HC-033

- A transformant *E. coli* DW/HC-033 was cultured similarly as in Example 6-1, and harvested after centrifugation,
- 20 suspended in a buffer solution (10mM Tris-HCl (pH 8.0) containing 0.1% Triton X-100, 2mM EDTA and 1mM PMSF) to lyse cells, and electrophoresed on 15% SDS-PAGE (see: Figure 8).

In Figure 8, lane M shows molecular size marker, lane

1 shows cell lysate before IPTG induction; lane 2 shows cell lysate of 24hrs cultured cells after IPTG induction; top arrow indicates locus of a chimeric protein containing cagA of H. pylori and A2 subunit of Vibrio cholerae toxin; and, bottom
5 arrow indicates locus of B subunit of Vibrio cholerae toxin.

As shown in Figure 8, it was found that the transformed E. coli DW/HC-033 successfully expresses a chimeric protein, which is designated as 'CagA/CTXA2B'.

10 Example 6-3: Expression of AlpA/CTXA2B in transformant

The transformant E. coli prepared in Example 5-3 was cultured in an analogous manner as in Example 6-1, to express desired recombinant protein, which is designated as
15 'AlpA/CTXA2B'.

Example 6-4: Expression of AlpB/CTXA2B in transformant

The transformant E. coli prepared in Example 5-4 was
20 cultured in an analogous manner as in Example 6-1, to express desired recombinant protein, which is designated as 'AlpB/CTXA2B'.

Example 6-5: Expression of FliQ/CTXA2B in transformant

25

The transformant E. coli prepared in Example 5-5 was cultured in an analogous manner as in Example 6-1, to express desired recombinant protein, which is designated as
'FliQ/CTXA2B'.

30

Example 6-6: Expression of BabA1/CTXA2B in transformant

The transformant E. coli prepared in Example 5-6 was cultured in an analogous manner as in Example 6-1, to express
35 desired recombinant protein, which is designated as 'BabA1/CTXA2B'.

Example 6-7: Expression of BabA2/CTXA2B in transformant

The transformant *E. coli* prepared in Example 5-7 was cultured in an analogous manner as in Example 6-1, to express
5 desired recombinant protein, which is designated as 'BabA2/CTXA2B'.

Example 6-8: Expression of UreC/CTXA2B in transformant

10 The transformant *E. coli* prepared in Example 5-8 was cultured in an analogous manner as in Example 6-1, to express desired recombinant protein, which is designated as 'UreC/CTXA2B'.

15 Example 6-9: Expression of in UreD/CTXA2B transformant

The transformant *E. coli* prepared in Example 5-9 was cultured in an analogous manner as in Example 6-1, to express
20 desired recombinant protein, which is designated as 'UreD/CTXA2B'.

Example 6-10: Expression of UreA/CTXA2B in transformant

25 The transformant *E. coli* prepared in Example 5-10 was cultured in an analogous manner as in Example 6-1, to express desired recombinant protein, which is designated as 'UreA/CTXA2B'.

30 Example 6-11: Expression of SodB/CTXA2B in transformant

The transformant *E. coli* prepared in Example 5-11 was cultured in an analogous manner as in Example 6-1, to express
35 desired recombinant protein, which is designated as 'SodB/CTXA2B'.

Example 6-12: Expression of UreI/CTXA2B in transformant

The transformant E. coli prepared in Example 5-12 was cultured in an analogous manner as in Example 6-1, to express desired recombinant protein, which is designated as 'UreI/CTXA2B'.

5

Example 6-13: Expression of UreE/CTXA2B in transformant

The transformant E. coli prepared in Example 5-13 was cultured in an analogous manner as in Example 6-1, to express
10 desired recombinant protein, which is designated as 'UreE/CTXA2B'.

Example 6-14: Expression of UreF/CTXA2B in transformant

15 The transformant E. coli prepared in Example 5-14 was cultured in an analogous manner as in Example 6-1, to express desired recombinant protein, which is designated as 'UreF/CTXA2B'.

20 Example 6-15: Expression of UreG/CTXA2B in transformant

The transformant E. coli prepared in Example 5-15 was cultured in an analogous manner as in Example 6-1, to express
25 desired recombinant protein, which is designated as 'UreG/CTXA2B'.

Example 6-16: Expression of UreH/CTXA2B in transformant

30 The transformant E. coli prepared in Example 5-16 was cultured in an analogous manner as in Example 6-1, to express desired recombinant protein, which is designated as 'UreH/CTXA2B'.

Example 6-17: Expression of FlaA/CTXA2B in transformant

35

The transformant E. coli prepared in Example 5-17 was cultured in an analogous manner as in Example 6-1, to express

desired recombinant protein, which is designated as 'FlaA/CTXA2B'.

Example 6-18: Expression of FlaB/CTXA2B in transformant

5

The transformant E. coli prepared in Example 5-18 was cultured in an analogous manner as in Example 6-1, to express desired recombinant protein, which is designated as 'FlaB/CTXA2B'.

10

Example 6-19: Expression of CatA/CTXA2B in transformant

The transformant E. coli prepared in Example 5-19 was cultured in an analogous manner as in Example 6-1, to express
15 desired recombinant protein, which is designated as 'CatA/CTXA2B'.

Example 6-20: Expression of VacA/CTXA2B in transformant

20

The transformant E. coli prepared in Example 5-20 was cultured in an analogous manner as in Example 6-1, to express desired recombinant protein, which is designated as 'VacA/CTXA2B'.

25 Example 6-21: Expression of BabB/CTXA2B in transformant

The transformant E. coli prepared in Example 5-21 was cultured in an analogous manner as in Example 6-1, to express desired recombinant protein, which is designated as
30 'BabB/CTXA2B'.

Example 7: Purification of chimeric proteins from the culture

Example 7-1: Purification of UreB/CTXA2B chimeric protein

35

The E. coli DW/HU-044 (KCCM-10124) was cultured in a LB medium and further cultured for 4 hours after IPTG induction.

The cultured cells were harvested by centrifugation and lysed with lysozyme. The lysed cells were washed several times with 0.5% Triton X-100, and washed with 8M urea to remove contaminated proteins. Then, inclusion bodies were dissolved in 8M urea and 0.1M DTT, diluted with glutathione redox buffer to refold the UreB/CTXA2B protein. Centrifugation was carried out to obtain the refolded chimeric protein, and size-exclusion chromatography was performed to obtain the UreB/CTXA2B chimeric protein only. SDS-PAGE, Western-blot and G_{M1}-ganglioside analysis confirmed that the obtained protein is UreB/CTXA2B chimeric protein.

Example 7-2: Purification of CagA/CTXA2B chimeric protein

15

The E. coli DW/HC-033 (KCCM-10123) was cultured in a LB medium and further cultured for 4 hours after IPTG induction. The cultured cells were harvested by centrifugation and lysed with lysozyme. The lysed cells were washed several times with 0.5% Triton X-100, and washed with 8M urea to remove contaminated proteins. Then, inclusion bodies were dissolved in 8M urea and 0.1M DTT, diluted with glutathione redox buffer to refold the CagA/CTXA2B protein. Centrifugation was carried out to obtain the refolded chimeric protein, and size-exclusion chromatography was performed to obtain the CagA/CTXA2B chimeric protein only. SDS-PAGE, Western-blot and G_{M1}-ganglioside analysis confirmed that the obtained protein is CagA/CTXA2B chimeric protein.

25
30

Example 7-3: Purification of AlpA/CTXA2B chimeric protein

Chimeric protein was expressed in Example 6-3, which was prepared and identified as AlpA/CTXA2B in accordance with the method described in Example 7-1.

35

Example 7-4: Purification of AlpB/CTXA2B chimeric protein

Chimeric protein was expressed in Example 6-4, which

was prepared and identified as AlpB/CTXA2B in accordance with the method described in Example 7-1.

Example 7-5: Purification of FliQ/CTXA2B chimeric protein

5

Chimeric protein was expressed in Example 6-5, which was prepared and identified as FliQ/CTXA2B in accordance with the method described in Example 7-1.

10 Example 7-6: Purification of BabA1/CTXA2B chimeric protein

Chimeric protein was expressed in Example 6-6, which was prepared and identified as BabA1/CTXA2B in accordance with the method described in Example 7-1.

15

Example 7-7: Purification of BabA2/CTXA2B chimeric protein

Chimeric protein was expressed in Example 6-7, which was prepared and identified as BabA2/CTXA2B in accordance with the method described in Example 7-1.

20

Example 7-8: Purification of UreC/CTXA2B chimeric protein

Chimeric protein was expressed in Example 6-8, which was prepared and identified as UreC/CTXA2B in accordance with the method described in Example 7-1.

25

Example 7-9: Purification of UreD/CTXA2B chimeric protein

Chimeric protein was expressed in Example 6-9, which was prepared and identified as UreD/CTXA2B in accordance with the method described in Example 7-1.

30

Example 7-10: Purification of UreA/CTXA2B chimeric protein

35

Chimeric protein was expressed in Example 6-10, which was prepared and identified as UreA/CTXA2B in accordance with the method described in Example 7-1.

Example 7-11: Purification of SodB/CTXA2B chimeric protein

Chimeric protein was expressed in Example 6-11, which
5 was prepared and identified as SodB/CTXA2B in accordance with
the method described in Example 7-1.

Example 7-12: Purification of UreI/CTXA2B chimeric protein

10 Chimeric protein was expressed in Example 6-12, which
was prepared and identified as UreI/CTXA2B in accordance with
the method described in Example 7-1.

Example 7-13: Purification of UreE/CTXA2B chimeric protein

15 Chimeric protein was expressed in Example 6-13, which
was prepared and identified as UreE/CTXA2B in accordance with
the method described in Example 7-1.

20 Example 7-14: Purification of UreF/CTXA2B chimeric protein

Chimeric protein was expressed in Example 6-14, which
was prepared and identified as UreF/CTXA2B in accordance with
the method described in Example 7-1.

25 Example 7-15: Purification of UreG/CTXA2B chimeric protein

Chimeric protein was expressed in Example 6-15, which
was prepared and identified as UreG/CTXA2B in accordance with
30 the method described in Example 7-1.

Example 7-16: Purification of UreH/CTXA2B chimeric protein

Chimeric protein was expressed in Example 6-16, which
35 was prepared and identified as UreH/CTXA2B in accordance with
the method described in Example 7-1.

Example 7-17: Purification of FlaA/CTXA2B chimeric protein

Chimeric protein was expressed in Example 6-17, which was prepared and identified as FlaA/CTXA2B in accordance with the method described in Example 7-1.

5

Example 7-18: Purification of FlaB/CTXA2B chimeric protein

Chimeric protein was expressed in Example 6-18, which was prepared and identified as FlaB/CTXA2B in accordance with the method described in Example 7-1.

10

Example 7-19: Purification of CatA/CTXA2B chimeric protein

Chimeric protein was expressed in Example 6-19, which was prepared and identified as CatA/CTXA2B in accordance with the method described in Example 7-1.

15

Example 7-20: Purification of VacA/CTXA2B chimeric protein

Chimeric protein was expressed in Example 6-20, which was prepared and identified as VacA/CTXA2B in accordance with the method described in Example 7-1.

20

Example 7-21: Purification of BabB/CTXA2B chimeric protein

25

Chimeric protein was expressed in Example 6-21, which was prepared and identified as BabB/CTXA2B in accordance with the method described in Example 7-1.

Example 8: Immunological reaction of the chimeric proteins

30

Example 8-1: Immunological reaction of the chimeric protein(UreB/CTXA2B)

In order to determine an antibody production rate of the UreB/CTXA2B chimeric protein obtained in Example 7-1, an animal experiment was carried out, in accordance with a protocol of the National Institutes of Health(NIH): That is, taking 4 Balb/C mice of 11 to 12-week as one experimental

35

group, 100 μ g of the UreB/CTXA2B chimeric protein dissolved in 0.5ml of 350mM NaHCO₃, 100 μ g of UreB dissolved in 0.5ml of 350mM NaHCO₃, and only 0.5ml of 350mM NaHCO₃ as a control were administered orally into stomach three times at 10-day intervals for immunization, respectively. The test animals were starved for 2 hours before the oral administration and for 1 hour after the oral administration.

Sera were obtained by tail bleeding at 1 day before immunization(0-day) and every week after immunization(8, 18, 28-day). Antibodies of extract of gastric juice were prepared by administering 0.5ml of a lavage solution(containing of 25mM NaCl, 40mM Na₂SO₄, 10mM KCl, 20mM NaHCO₃ and 48.5mM polyethyleneglycol) four times at 15-minute intervals into mice, injecting 0.2ml of pilocarpine(0.5mg/ml) peritoneally at 30 minutes after the last administration and obtaining extracts of gastric juice from mice at 30 minutes after injection.

Quantitation of the antibody produced by UreB/CTXA2B was carried out using ELISA as followings: That is, after sera and extract of gastric juice were treated into a 96-well plate treated with goat anti-mouse IgG and IgA antibodies, goat peroxidase-conjugated antibodies against each isotype of mouse antibody as secondary antibodies were treated. Absorbance at 405nm was measured using p-nitrophenyl phosphate as substrates of peroxidase to determine an antibody production rate. As a result, it was found that: when the UreB/CTXA2B chimeric protein was administered, the amount of serum IgG increased remarkably after 18 days and increased 3-fold or more compared with mice administered with only UreB(see: Figure 9). Also, it was revealed that amount of IgA in extract of gastric juice increased 3-fold or more compared with mice administered with only UreB(see: Figure 10).

Example 8-2: Immunological reaction of the chimeric protein(CatA/CTXA2B)

In order to determine an antibody production rate of the CatA/CTXA2B chimeric protein obtained in Example 7-2,

an animal experiment was carried out, in accordance with a protocol of the National Institutes of Health (NIH): That is, taking 4 Balb/C mice of 11 to 12-week as one experimental group, 100 μ g of the CatA/CTXA2B chimeric protein dissolved in 0.5ml of 350mM NaHCO₃, 100 μ g of CatA dissolved in 0.5ml of 350mM NaHCO₃, and only 0.5ml of 350mM NaHCO₃ as a control were administered orally into stomach three times at 10-day intervals for immunization, respectively. The test animals were starved for 2 hours before the oral administration and for 1 hour after the oral administration. Sera were obtained by tail bleeding at 1 day before immunization (0-day) and every week after immunization (8, 18, 28-day). Antibodies of extract of gastric juice were prepared by administering 0.5ml of a lavage solution (containing of 25mM NaCl, 40mM Na₂SO₄, 10mM KCl, 20mM NaHCO₃ and 48.5mM polyethyleneglycol) four times at 15-minute intervals into mice, injecting 0.2ml of pilocarpine (0.5mg/ml) peritoneally at 30 minutes after the last administration and obtaining extracts of gastric juice from mice at 30 minutes after injection.

Quantitation of the antibody produced by CatA/CTXA2B was carried out using ELISA as followings: That is, after sera and extract of gastric juice were treated into a 96-well plate treated with goat anti-mouse IgG and IgA antibodies, goat peroxidase-conjugated antibodies against each isotype of mouse antibody as secondary antibodies were treated. Absorbance at 405nm was measured using p-nitrophenyl phosphate as substrates of peroxidase to determine an antibody production rate. As a result, it was found that: when the CatA/CTXA2B chimeric protein was administered, the amount of serum IgG increased remarkably after 18 days and increased 0.3-fold or more compared with mice administered with CatA only (see: Figure 11). Also, it was revealed that amount of IgA in extract of gastric juice increased 0.3-fold or more compared with mice administered with only CatA (see: Figure 12).

Example 8-3: Immunological reaction of the chimeric protein (AlpA/CTXA2B)

The animal experiment and antibody quantitation were carried out in an analogous manner as in Example 8-1, with an exception that AlpA/CTXA2B chimeric protein was employed for the determination of antibody productivity of AlpA/CTXA2B prepared in Example 7-3. As a result, it was found that: when the AlpA/CTXA2B chimeric protein was administered, the amount of serum IgG increased remarkably after 18 days compared with mice administered with only AlpA. Also, it was revealed that amount of IgA in extract of gastric juice increased compared with mice administered with only AlpA.

Example 8-4: Immunological reaction of the chimeric protein (AlpB/CTXA2B)

The animal experiment and antibody quantitation were carried out in an analogous manner as in Example 8-1, with an exception that AlpB/CTXA2B chimeric protein was employed for the determination of antibody productivity of AlpB/CTXA2B prepared in Example 7-4. As a result, it was found that: when the AlpB/CTXA2B chimeric protein was administered, the amount of serum IgG increased remarkably after 18 days compared with mice administered with only AlpB. Also, it was revealed that amount of IgA in extract of gastric juice increased compared with mice administered with only AlpB.

Example 8-5: Immunological reaction of the chimeric protein (FliQ/CTXA2B)

The animal experiment and antibody quantitation were carried out in an analogous manner as in Example 8-1, with an exception that FliQ/CTXA2B chimeric protein was employed for the determination of antibody productivity of FliQ/CTXA2B prepared in Example 7-5. As a result, it was found that: when the FliQ/CTXA2B chimeric protein was administered, the amount of serum IgG increased remarkably after 18 days compared with mice administered with only AlpA. Also, it was revealed that amount of IgA in extract of gastric juice increased compared with mice administered with only FliQ.

Example 8-6: Immunological reaction of the chimeric protein(BabA1/CTXA2B)

5 The animal experiment and antibody quantitation were carried out in an analogous manner as in Example 8-1, with an exception that BabA1/CTXA2B chimeric protein was employed for the determination of antibody productivity of BabA1/CTXA2B prepared in Example 7-6. As a result, it was
10 found that: when the BabA1/CTXA2B chimeric protein was administered, the amount of serum IgG increased remarkably after 18 days compared with mice administered with only BabA1. Also, it was revealed that amount of IgA in extract of gastric juice increased compared with mice administered with only
15 BabA1.

Example 8-7: Immunological reaction of the chimeric protein(BabA2/CTXA2B)

20 The animal experiment and antibody quantitation were carried out in an analogous manner as in Example 8-1, with an exception that BabA2/CTXA2B chimeric protein was employed for the determination of antibody productivity of BabA2/CTXA2B prepared in Example 7-7. As a result, it was
25 found that: when the BabA2/CTXA2B chimeric protein was administered, the amount of serum IgG increased remarkably after 18 days compared with mice administered with only BabA2. Also, it was revealed that amount of IgA in extract of gastric juice increased compared with mice administered with only
30 BabA2.

Example 8-8: Immunological reaction of the chimeric protein(UreC/CTXA2B)

35 The animal experiment and antibody quantitation were carried out in an analogous manner as in Example 8-1, with an exception that UreC/CTXA2B chimeric protein was employed for the determination of antibody productivity of

UreC/CTXA2B prepared in Example 7-8. As a result, it was found that: when the UreC/CTXA2B chimeric protein was administered, the amount of serum IgG increased remarkably after 18 days compared with mice administered with only UreC. Also, it was
5 revealed that amount of IgA in extract of gastric juice increased compared with mice administered with only UreC.

Example 8-9: Immunological reaction of the chimeric protein(UreD/CTXA2B)

10

The animal experiment and antibody quantitation were carried out in an analogous manner as in Example 8-1, with an exception that UreD/CTXA2B chimeric protein was employed for the determination of antibody productivity of
15 UreD/CTXA2B prepared in Example 7-9. As a result, it was found that: when the UreD/CTXA2B chimeric protein was administered, the amount of serum IgG increased remarkably after 18 days compared with mice administered with only UreD. Also, it was revealed that amount of IgA in extract of gastric juice
20 increased compared with mice administered with only UreD.

Example 8-10: Immunological reaction of the chimeric protein(UreA/CTXA2B)

25

The animal experiment and antibody quantitation were carried out in an analogous manner as in Example 8-1, with an exception that UreA/CTXA2B chimeric protein was employed for the determination of antibody productivity of UreA/CTXA2B prepared in Example 7-10. As a result, it was
30 found that: when the UreA/CTXA2B chimeric protein was administered, the amount of serum IgG increased remarkably after 18 days compared with mice administered with only UreA. Also, it was revealed that amount of IgA in extract of gastric juice increased compared with mice administered with only
35 UreA.

Example 8-11: Immunological reaction of the chimeric protein(SodB/CTXA2B)

The animal experiment and antibody quantitation were carried out in an analogous manner as in Example 8-1, with an exception that SodB/CTXA2B chimeric protein was employed for the determination of antibody productivity of SodB/CTXA2B prepared in Example 7-11. As a result, it was found that: when the SodB/CTXA2B chimeric protein was administered, the amount of serum IgG increased remarkably after 18 days compared with mice administered with only SodB. Also, it was revealed that amount of IgA in extract of gastric juice increased compared with mice administered with only SodB.

Example 8-12: Immunological reaction of the chimeric protein(UreI/CTXA2B)

The animal experiment and antibody quantitation were carried out in an analogous manner as in Example 8-1, with an exception that UreI/CTXA2B chimeric protein was employed for the determination of antibody productivity of UreI/CTXA2B prepared in Example 7-12. As a result, it was found that: when the UreI/CTXA2B chimeric protein was administered, the amount of serum IgG increased remarkably after 18 days compared with mice administered with only UreI. Also, it was revealed that amount of IgA in extract of gastric juice increased compared with mice administered with only UreI.

Example 8-13: Immunological reaction of the chimeric protein(UreE/CTXA2B)

The animal experiment and antibody quantitation were carried out in an analogous manner as in Example 8-1, with an exception that UreE/CTXA2B chimeric protein was employed for the determination of antibody productivity of UreE/CTXA2B prepared in Example 7-13. As a result, it was found that: when the UreE/CTXA2B chimeric protein was

administered, the amount of serum IgG increased remarkably after 18 days compared with mice administered with only UreE.

Also, it was revealed that amount of IgA in extract of gastric juice increased compared with mice administered with only UreE.

Example 8-15: Immunological reaction of the chimeric protein(UreG/CTXA2B)

The animal experiment and antibody quantitation were carried out in an analogous manner as in Example 8-1, with an exception that UreG/CTXA2B chimeric protein was employed for the determination of antibody productivity of UreG/CTXA2B prepared in Example 7-15. As a result, it was found that: when the UreG/CTXA2B chimeric protein was administered, the amount of serum IgG increased remarkably after 18 days compared with mice administered with only UreG.

Also, it was revealed that amount of IgA in extract of gastric juice increased compared with mice administered with only UreG.

Example 8-16: Immunological reaction of the chimeric protein(UreH/CTXA2B)

The animal experiment and antibody quantitation were carried out in an analogous manner as in Example 8-1, with an exception that UreH/CTXA2B chimeric protein was employed for the determination of antibody productivity of UreH/CTXA2B prepared in Example 7-16. As a result, it was found that: when the UreH/CTXA2B chimeric protein was administered, the amount of serum IgG increased remarkably after 18 days compared with mice administered with only UreH.

Also, it was revealed that amount of IgA in extract of gastric juice increased compared with mice administered with only UreH.

Example 8-17: Immunological reaction of the chimeric protein(FlaA/CTXA2B)

The animal experiment and antibody quantitation were carried out in an analogous manner as in Example 8-1, with an exception that FlaA/CTXA2B chimeric protein was employed for the determination of antibody productivity of FlaA/CTXA2B prepared in Example 7-17. As a result, it was found that: when the FlaA/CTXA2B chimeric protein was administered, the amount of serum IgG increased remarkably after 18 days compared with mice administered with only FlaA. Also, it was revealed that amount of IgA in extract of gastric juice increased compared with mice administered with only FlaA.

Example 8-18: Immunological reaction of the chimeric protein(FlaB/CTXA2B)

The animal experiment and antibody quantitation were carried out in an analogous manner as in Example 8-1, with an exception that FlaB/CTXA2B chimeric protein was employed for the determination of antibody productivity of FlaB/CTXA2B prepared in Example 7-18. As a result, it was found that: when the FlaB/CTXA2B chimeric protein was administered, the amount of serum IgG increased remarkably after 18 days compared with mice administered with only FlaB. Also, it was revealed that amount of IgA in extract of gastric juice increased compared with mice administered with only FlaB.

Example 8-19: Immunological reaction of the chimeric protein(CatA/CTXA2B)

The animal experiment and antibody quantitation were carried out in an analogous manner as in Example 8-1, with an exception that CatA/CTXA2B chimeric protein was employed for the determination of antibody productivity of CatA/CTXA2B prepared in Example 7-19. As a result, it was found that: when the CatA/CTXA2B chimeric protein was

administered, the amount of serum IgG increased remarkably after 18 days compared with mice administered with only CatA.

Also, it was revealed that amount of IgA in extract of gastric juice increased compared with mice administered with only CatA.

Example 8-20: Immunological reaction of the chimeric protein(VacA/CTXA2B)

10 The animal experiment and antibody quantitation were carried out in an analogous manner as in Example 8-1, with an exception that VacA/CTXA2B chimeric protein was employed for the determination of antibody productivity of VacA/CTXA2B prepared in Example 7-20. As a result, it was
15 found that: when the VacA/CTXA2B chimeric protein was administered, the amount of serum IgG increased remarkably after 18 days compared with mice administered with only VacA.

Also, it was revealed that amount of IgA in extract of gastric juice increased compared with mice administered with only
20 VacA.

Example 8-21: Immunological reaction of the chimeric protein(BabB/CTXA2B)

25 The animal experiment and antibody quantitation were carried out in an analogous manner as in Example 8-1, with an exception that BabB/CTXA2B chimeric protein was employed for the determination of antibody productivity of BabB/CTXA2B prepared in Example 7-8. As a result, it was found
30 that: when the BabB/CTXA2B chimeric protein was administered, the amount of serum IgG increased remarkably after 18 days compared with mice administered with only BabB. Also, it was revealed that amount of IgA in extract of gastric juice increased compared with mice administered with only BabB.

35

Example 9: Effect of the chimeric proteins as a vaccine for H. pylori-associated disease

Example 9-1: Effect of the UreB/CTXA2B chimeric protein
as a vaccine

Effect of the UreB/CTXA2B chimeric protein as an active
5 ingredient for a potential vaccine against H. pylori was
determined by investigating infection of mice immunized with
the UreB/CTXA2B chimeric protein and UreB, respectively,
with H. pylori.

After 11 to 12 C57BL/6 mice were taken as one
10 experimental group, 100ug of the UreB/CTXA2B chimeric
protein dissolved in 0.5ml of a physiological saline, 100ug
of UreB dissolved in 0.5ml of a physiological saline, and
only 0.5ml of a physiological saline as a control were
administered orally into stomach three times at 1-week
15 intervals using polyethylene catecher, respectively. At 7
days after the last administration, H. pylori Q-
35 (obtainable from the College of Medicine, Kyungsang
National University, Korea) strain was suspended in 0.1ml
of a physiological saline in a concentration of 10^7 CFU and
20 administered into mice three times at 2-day intervals using
polyethylene catecher.

After 2 weeks, pylori of stomachs of all mice were cut
in a size of 0.5cm x 0.5cm and soaked in 1ml of a sterilized
Brain Heart Infusion broth (Difco, U.S.A.). After each
25 sample was diluted with a sterilized physiological saline
in a serial dilution of 10-fold, 100 μ l of the sample was
inoculated in a medium (Blood Agar Base No.2 containing 5%
horse serum, 10mg/ml vancomycin, 5mg/ml trimethoprim and
4mg/ml amphotericin B) and cultured at 37°C for 5 days in a
30 CO₂ incubator (10% CO₂, humidity of 90% or more). After
cultivation, number of colonies showing appearance of H.
pylori was measured and the corresponding colonies were
transferred onto a fresh medium and cultured for 3 days.

The cultured strains were suspended in 500ml of a
35 physiological saline and catalase, oxidase and urease
reactions were carried out as followings: First, 100ul of
each sample was added to 1ml of an urease-detecting
reagent (20g/l urea, 0.05% (w/v) phenolred, 0.044g/l NaH₂PO₄·H₂O,
1.02g/l Na₂HPO₄, 0.2g/l NaN₃), vortexed well, and incubated

at room temperature for 4 hours, and its absorbance at 550nm was measured. In this connection, a sample having a value of 0.1 or more higher than a control without a sample was considered as a sample showing a positive reaction. On the other hand, in order to detect catalase, one drop of a sample was added onto a slide glass and one drop of 3% H₂O₂ was dropped onto it. In this connection, a reaction showing generation of gas and bubbles was considered as a positive reaction.

Also, in order to detect oxidase, one drop of a sample was added onto a filter paper and one drop of 1% N,N'-tetramethyl-p-phenylenediamine dissolved in isoamylalcohol was dropped onto it. In this connection, a reaction showing a purple color within several minutes was considered as a positive reaction.

A sample showing positive reactions in all three experiments mentioned as above was regarded as a sample infected with H. pylori. As can be seen in Table 2 below, the experiments revealed that the experimental groups administered with UreB/CTXA2B and UreB showed prevention rate of 75% and 27%, respectively. On the other hand, it was found that all mice of the control group administered with only a physiological saline were infected with H. pylori, which showed no preventive effect.

Table 2: Infection of mice immunized with the UreB/CTXA2B chimeric protein and UreB, respectively, with H. pylori

Experimental group	Infecting strain	Number of mice showing formation of colonies/ number of all mice	Prevention rate (%)
Control	Q-35	12/12	0
UreB	Q-35	8/11	27
UreB/CTXA2B chimeric protein	Q-35	3/12	75

Example 9-2: Effect of the CagA/CTXA2B chimeric protein as a vaccine

5 Effect of the CagA/CTXA2B chimeric protein as an active ingredient for a potential vaccine against H. pylori was determined by investigating infection of mice immunized with the CagA/CTXA2B chimeric protein and CagA, respectively, with H. pylori.

10 After 8 to 11 C57BL/6 mice were taken as one experimental group, 100ug of the CagA/CTXA2B chimeric protein dissolved in 0.5ml of a physiological saline, 100ug of CagA dissolved in 0.5ml of a physiological saline, and only 0.5ml of a physiological saline as a control were administered orally
15 into stomach three times at 1-week intervals using polyethylene catecher, respectively. At 7 days after the last administration, H. pylori (Q-35, ATCC 11637) strain was suspended in 0.1ml of a physiological saline in a concentration of 10^7 CFU and administered into mice three
20 times at 2-day intervals using polyethylene catecher.

 After 2 weeks, H. pylori of stomachs of all mice were cut in a size of 0.5cm x 0.5cm and soaked in 1ml of a sterilized Brain Heart Infusion broth (Difco, U.S.A.). After each sample was diluted with a sterilized physiological saline
25 in a serial dilution of 10-fold, 100 μ l of the sample was inoculated in a medium (Blood Agar Base No.2 containing 5% horse serum, 10mg/ml vancomycin, 5mg/ml trimethoprim and 4mg/ml amphotericin B) and cultured at 37°C for 5 days in a CO₂ incubator (10% CO₂, humidity of 90% or more). After
30 cultivation, number of colonies showing appearance of H. pylori was measured and the corresponding colonies were transferred onto a fresh medium and cultured for 3 days.

 The cultured strains were suspended in 500ml of a physiological saline and catalase, oxidase and urease reactions were carried out as followings: First, 100ul of
35 each sample was added to 1ml of an urease-detecting reagent (20g/l urea, 0.05% (w/v) phenolred, 0.044g/l NaH₂PO₄·H₂O, 1.02g/l Na₂HPO₄, 0.2g/l NaN₃), vortexed well, and incubated at room temperature for 4 hours, and its absorbance at 550nm

was measured. In this connection, a sample having a value of 0.1 or more higher than a control without a sample was considered as a sample showing a positive reaction. On the other hand, in order to detect catalase, one drop of a sample was added onto a slide glass and one drop of 3% H₂O₂ was dropped onto it. In this connection, a reaction showing generation of gas and bubbles was considered as a positive reaction. Also, in order to detect oxidase, one drop of a sample was added onto a filter paper and one drop of 1% N,N'-tetramethyl-p-phenylenediamine dissolved in isoamylalcohol was dropped onto it. In this connection, a reaction showing a purple color within several minutes was considered as a positive reaction.

A sample showing positive reactions in all three experiments mentioned as above was regarded as a sample infected with H. pylori. As can be seen in Table 4 below, the experiments revealed that the experimental groups administered with CagA/CTXA2B and CagA showed prevention rate of 80% and 55%, respectively. On the other hand, all mice of the control group administered with only a physiological saline were infected with H. pylori, which showed no preventive effect.

Table 3: Infection of mice immunized with the CagA/CTXA2B chimeric protein and CagA, respectively, with H. pylori

Experimental group	Infecting strain	Number of mice showing formation of colonies/ number of all mice	Prevention rate (%)
Control	Q-35	8/8	0
CagA	Q-35	5/11	55
CagA/CTXA2B chimeric protein	Q-35	2/10	80

Example 9-3: Effect of the AlpA/CTXA2B chimeric protein
as a vaccine

5 Infectivity of the mice immunized with AlpA/CTXA2B
chimeric protein and AlpA against *H. pylori* was investigated
in an analogous manner as in Example 9-1, to determine the
effect of AlpA/CTXA2B as a potential vaccine for *H. pylori*,
with an exception that AlpA/CTXA2B chimeric protein was
10 employed instead of UreB/CTXA2B. As a result, it was
determined that the experimental groups administered with
AlpA/CTXA2B and AlpA showed prevention rate of 75% and 50%,
respectively. On the other hand, all mice of the control
group administered with only a physiological saline were
15 infected with *H. pylori*, which showed no preventive effect.

Example 9-4: Effect of the AlpB/CTXA2B chimeric protein
as a vaccine

20 Infectivity of the mice immunized with AlpB/CTXA2B
chimeric protein and AlpB against *H. pylori* was investigated
in an analogous manner as in Example 9-1, to determine the
effect of AlpB/CTXA2B as a potential vaccine for *H. pylori*,
with an exception that AlpB/CTXA2B chimeric protein was
25 employed instead of UreB/CTXA2B. As a result, it was
determined that the experimental groups administered with
AlpB/CTXA2B and AlpA showed prevention rate of 65% and 53%,
respectively. On the other hand, all mice of the control
group administered with only a physiological saline were
30 infected with *H. pylori*, which showed no preventive effect.

Example 9-5: Effect of the FliQ/CTXA2B chimeric protein
as a vaccine

35 Infectivity of the mice immunized with FliQ/CTXA2B
chimeric protein and FliQ against *H. pylori* was investigated
in an analogous manner as in Example 9-1, to determine the

effect of FliQ/CTXA2B as a potential vaccine for *H. pylori*, with an exception that FliQ/CTXA2B chimeric protein was employed instead of FliQ/CTXA2B. As a result, it was determined that the experimental groups administered with
5 FliQ/CTXA2B and FliQ showed prevention rate of 75% and 57%, respectively. On the other hand, all mice of the control group administered with only a physiological saline were infected with *H. pylori*, which showed no preventive effect.

10 Example 9-6: Effect of the BabA1/CTXA2B chimeric protein as a vaccine

Infectivity of the mice immunized with BabA1/CTXA2B chimeric protein and BabA1 against *H. pylori* was investigated
15 in an analogous manner as in Example 9-1, to determine the effect of BabA1/CTXA2B as a potential vaccine for *H. pylori*, with an exception that BabA1/CTXA2B chimeric protein was employed instead of UreB/CTXA2B. As a result, it was determined that the experimental groups administered with
20 BabA1/CTXA2B and BabA1 showed prevention rate of 80% and 57%, respectively. On the other hand, all mice of the control group administered with only a physiological saline were infected with *H. pylori*, which showed no preventive effect.

25 Example 9-7: Effect of the BabA2/CTXA2B chimeric protein as a vaccine

Infectivity of the mice immunized with BabA2/CTXA2B chimeric protein and BabA2 against *H. pylori* was investigated
30 in an analogous manner as in Example 9-1, to determine the effect of BabA2/CTXA2B as a potential vaccine for *H. pylori*, with an exception that BabA2/CTXA2B chimeric protein was employed instead of UreB/CTXA2B. As a result, it was determined that the experimental groups administered with
35 BabA2/CTXA2B and BabA2 showed prevention rate of 75% and 55%, respectively. On the other hand, all mice of the control group administered with only a physiological saline were

infected with H. pylori, which showed no preventive effect.

Example 9-8: Effect of the UreC/CTXA2B chimeric protein
as a vaccine

5

Infectivity of the mice immunized with UreC/CTXA2B chimeric protein and UreC against H. pylori was investigated in an analogous manner as in Example 9-1, to determine the effect of UreC/CTXA2B as a potential vaccine for H. pylori,
10 with an exception that UreC/CTXA2B chimeric protein was employed instead of UreB/CTXA2B. As a result, it was determined that the experimental groups administered with UreC/CTXA2B and UreC showed prevention rate of 78% and 60%, respectively. On the other hand, all mice of the control
15 group administered with only a physiological saline were infected with H. pylori, which showed no preventive effect.

Example 9-9: Effect of the UreD/CTXA2B chimeric protein
as a vaccine

20

Infectivity of the mice immunized with UreD/CTXA2B chimeric protein and UreD against H. pylori was investigated in an analogous manner as in Example 9-1, to determine the effect of UreD/CTXA2B as a potential vaccine for H. pylori,
25 with an exception that UreD/CTXA2B chimeric protein was employed instead of UreB/CTXA2B. As a result, it was determined that the experimental groups administered with UreD/CTXA2B and UreD showed prevention rate of 70% and 52%, respectively. On the other hand, all mice of the control
30 group administered with only a physiological saline were infected with H. pylori, which showed no preventive effect.

Example 9-10: Effect of the UreA/CTXA2B chimeric protein
as a vaccine

35

Infectivity of the mice immunized with UreA/CTXA2B chimeric protein and UreA against H. pylori was investigated in an analogous manner as in Example 9-1, to determine the

effect of UreA/CTXA2B as a potential vaccine for *H. pylori*, with an exception that UreA/CTXA2B chimeric protein was employed instead of UreB/CTXA2B. As a result, it was determined that the experimental groups administered with UreA/CTXA2B and UreA showed prevention rate of 70% and 50%, respectively. On the other hand, all mice of the control group administered with only a physiological saline were infected with *H. pylori*, which showed no preventive effect.

10 Example 9-11: Effect of the SodB/CTXA2B chimeric protein as a vaccine

Infectivity of the mice immunized with SodB/CTXA2B chimeric protein and SodB against *H. pylori* was investigated in an analogous manner as in Example 9-1, to determine the effect of SodB/CTXA2B as a potential vaccine for *H. pylori*, with an exception that SodB/CTXA2B chimeric protein was employed instead of UreB/CTXA2B. As a result, it was determined that the experimental groups administered with SodB/CTXA2B and SodB showed prevention rate of 70% and 55%, respectively. On the other hand, all mice of the control group administered with only a physiological saline were infected with *H. pylori*, which showed no preventive effect.

25 Example 9-12: Effect of the UreI/CTXA2B chimeric protein as a vaccine

Infectivity of the mice immunized with UreI/CTXA2B chimeric protein and UreI against *H. pylori* was investigated in an analogous manner as in Example 9-1, to determine the effect of UreI/CTXA2B as a potential vaccine for *H. pylori*, with an exception that UreI/CTXA2B chimeric protein was employed instead of UreB/CTXA2B. As a result, it was determined that the experimental groups administered with UreI/CTXA2B and UreI showed prevention rate of 65% and 53%, respectively. On the other hand, all mice of the control group administered with only a physiological saline were

infected with H. pylori, which showed no preventive effect.

Example 9-13: Effect of the UreE/CTXA2B chimeric protein
as a vaccine

5

Infectivity of the mice immunized with UreE/CTXA2B chimeric protein and UreE against H. pylori was investigated in an analogous manner as in Example 9-1, to determine the effect of UreE/CTXA2B as a potential vaccine for H. pylori,
10 with an exception that UreE/CTXA2B chimeric protein was employed instead of UreB/CTXA2B. As a result, it was determined that the experimental groups administered with UreE/CTXA2B and UreI showed prevention rate of 70% and 55%, respectively. On the other hand, all mice of the control
15 group administered with only a physiological saline were infected with H. pylori, which showed no preventive effect.

Example 9-14: Effect of the UreF/CTXA2B chimeric protein
as a vaccine

20

Infectivity of the mice immunized with UreF/CTXA2B chimeric protein and UreF against H. pylori was investigated in an analogous manner as in Example 9-1, to determine the effect of UreF/CTXA2B as a potential vaccine for H. pylori,
25 with an exception that UreF/CTXA2B chimeric protein was employed instead of UreB/CTXA2B. As a result, it was determined that the experimental groups administered with UreF/CTXA2B and UreF showed prevention rate of 75% and 55%, respectively. On the other hand, all mice of the control
30 group administered with only a physiological saline were infected with H. pylori, which showed no preventive effect.

Example 9-15: Effect of the UreG/CTXA2B chimeric protein
as a vaccine

35

Infectivity of the mice immunized with UreG/CTXA2B chimeric protein and UreG against H. pylori was investigated

in an analogous manner as in Example 9-1, to determine the effect of UreG/CTXA2B as a potential vaccine for *H. pylori*, with an exception that UreG/CTXA2B chimeric protein was employed instead of UreB/CTXA2B. As a result, it was
5 determined that the experimental groups administered with UreG/CTXA2B and UreG showed prevention rate of 78% and 53%, respectively. On the other hand, all mice of the control group administered with only a physiological saline were infected with *H. pylori*, which showed no preventive effect.

10

Example 9-16: Effect of the UreH/CTXA2B chimeric protein as a vaccine

Infectivity of the mice immunized with UreH/CTXA2B
15 chimeric protein and UreH against *H. pylori* was investigated in an analogous manner as in Example 9-1, to determine the effect of UreH/CTXA2B as a potential vaccine for *H. pylori*, with an exception that UreH/CTXA2B chimeric protein was employed instead of UreB/CTXA2B. As a result, it was
20 determined that the experimental groups administered with UreH/CTXA2B and UreH showed prevention rate of 65% and 45%, respectively. On the other hand, all mice of the control group administered with only a physiological saline were infected with *H. pylori*, which showed no preventive effect.

25

Example 9-17: Effect of the FlaA/CTXA2B chimeric protein as a vaccine

Infectivity of the mice immunized with FlaA/CTXA2B
30 chimeric protein and FlaA against *H. pylori* was investigated in an analogous manner as in Example 9-1, to determine the effect of FlaA/CTXA2B as a potential vaccine for *H. pylori*, with an exception that FlaA/CTXA2B chimeric protein was employed instead of UreB/CTXA2B. As a result, it was
35 determined that the experimental groups administered with FlaA/CTXA2B and FlaA showed prevention rate of 70% and 52%, respectively. On the other hand, all mice of the control

Infectivity of the mice immunized with FlaB/CTXA2B chimeric protein and FlaB against *H. pylori* was investigated in an analogous manner as in Example 9-1, to determine the effect of FlaB/CTXA2B as a potential vaccine for *H. pylori*, with an exception that FlaB/CTXA2B chimeric protein was employed instead of UreB/CTXA2B. As a result, it was determined that the experimental groups administered with FlaB/CTXA2B and FlaB showed prevention rate of 78% and 50%, respectively. On the other hand, all mice of the control group administered with only a physiological saline were infected with *H. pylori*, which showed no preventive effect.

Infectivity of the mice immunized with CatA/CTXA2B chimeric protein and CatA against *H. pylori* was investigated in an analogous manner as in Example 9-1, to determine the effect of CatA/CTXA2B as a potential vaccine for *H. pylori*, with an exception that CatA/CTXA2B chimeric protein was employed instead of UreB/CTXA2B. As a result, it was determined that the experimental groups administered with CatA/CTXA2B and CatA showed prevention rate of 75% and 50%, respectively. On the other hand, all mice of the control group administered with only a physiological saline were infected with *H. pylori*, which showed no preventive effect.

Infectivity of the mice immunized with VacA/CTXA2B

chimeric protein and VacA against *H. pylori* was investigated in an analogous manner as in Example 9-1, to determine the effect of VacA/CTXA2B as a potential vaccine for *H. pylori*, with an exception that VacA/CTXA2B chimeric protein was employed instead of UreB/CTXA2B. As a result, it was determined that the experimental groups administered with VacA/CTXA2B and VacA showed prevention rate of 68% and 53%, respectively. On the other hand, all mice of the control group administered with only a physiological saline were infected with *H. pylori*, which showed no preventive effect.

Example 9-21: Effect of the BabB/CTXA2B chimeric protein as a vaccine

Infectivity of the mice immunized with BabB/CTXA2B chimeric protein and BabB against *H. pylori* was investigated in an analogous manner as in Example 9-1, to determine the effect of BabB/CTXA2B as a potential vaccine for *H. pylori*, with an exception that BabB/CTXA2B chimeric protein was employed instead of UreB/CTXA2B. As a result, it was determined that the experimental groups administered with BabB/CTXA2B and BabB showed prevention rate of 72% and 53%, respectively. On the other hand, all mice of the control group administered with only a physiological saline were infected with *H. pylori*, which showed no preventive effect.

As shown in Examples 9-1 to 9-21, it was clearly demonstrated that: the chimeric proteins of antigenic proteins of *H. pylori* and A2 and B subunits of *Vibrio cholerae*, can induce specific antibodies neutralizing *H. pylori* and be used as a preventive or therapeutic vaccine for *H. pylori*-associated diseases.

Preparative Example 1: Solution containing UreB/CTXA2B chimeric protein

UreB/CTXA2B chimeric protein

100 μ g

	0.6M sodium bicarbonate	250 μ l
	Distilled water	250 μ l
5	<hr/>	
	Total	500 μ l

A solution containing UreB/CTXA2B chimeric protein was prepared as described above.

10

Preparative Example 2: Solution containing CagA/CTXA2B chimeric protein

	CagA/CTXA2B chimeric protein	100 μ g
15	0.6M sodium bicarbonate	250 μ l
	Distilled water	250 μ l
	<hr/>	
20	Total	500 μ l

A solution containing CagA/CTXA2B chimeric protein was prepared as described above.

25 Preparative Example 3: Solution containing AlpA/CTXA2B chimeric protein

	AlpA/CTXA2B chimeric protein	100 μ g
30	0.6M sodium bicarbonate	250 μ l
	Distilled water	250 μ l
	<hr/>	
35	Total	500 μ l

A solution containing AlpA/CTXA2B chimeric protein was prepared as described above.

Preparative Example 4: Solution containing AlpB/CTXA2B
chimeric protein

5	AlpB/CTXA2B chimeric protein	100 μ g
	0.6M sodium bicarbonate	250 μ l
	Distilled water	250 μ l
10	<hr/>	
	Total	500 μ l

A solution containing AlpB/CTXA2B chimeric protein was prepared as described above.

15

Preparative Example 5: Solution containing FliQ/CTXA2B
chimeric protein

20	FliQ/CTXA2B chimeric protein	100 μ g
	0.6M sodium bicarbonate	250 μ l
	Distilled water	250 μ l
25	<hr/>	
	Total	500 μ l

A solution containing FliQ/CTXA2B chimeric protein was prepared as described above.

30 Preparative Example 6: Solution containing BabA1/CTXA2B
chimeric protein

	BabA1/CTXA2B chimeric protein	100 μ g
35	0.6M sodium bicarbonate	250 μ l
	Distilled water	250 μ l

Total	500 μ l
-------	-------------

A solution containing BabA1/CTXA2B chimeric protein was
5 prepared as described above.

Preparative Example 7: Solution containing BabA2/CTXA2B
chimeric protein

10	BabA2/CTXA2B chimeric protein	100 μ g
	0.6M sodium bicarbonate	250 μ l
	Distilled water	250 μ l
15	<hr/>	
	Total	500 μ l

A solution containing BabA2/CTXA2B chimeric protein was
prepared as described above.

20

Preparative Example 8: Solution containing UreC/CTXA2B
chimeric protein

25	UreC/CTXA2B chimeric protein	100 μ g
	0.6M sodium bicarbonate	250 μ l
	Distilled water	250 μ l
30	<hr/>	
	Total	500 μ l

A solution containing UreC/CTXA2B chimeric protein was
prepared as described above.

35 Preparative Example 9: Solution containing UreD/CTXA2B
chimeric protein

70

	UreD/CTXA2B chimeric protein	100 μ g
	0.6M sodium bicarbonate	250 μ l
5	Distilled water	250 μ l
<hr/>		
	Total	500 μ l

10 A solution containing UreD/CTXA2B chimeric protein was prepared as described above.

Preparative Example 10: Solution containing UreA/CTXA2B chimeric protein

15	UreA/CTXA2B chimeric protein	100 μ g
	0.6M sodium bicarbonate	250 μ l
	Distilled water	250 μ l
20	<hr/>	
	Total	500 μ l

25 A solution containing UreA/CTXA2B chimeric protein was prepared as described above.

Preparative Example 11: Solution containing SodB/CTXA2B chimeric protein

30	SodB/CTXA2B chimeric protein	100 μ g
	0.6M sodium bicarbonate	250 μ l
	Distilled water	250 μ l
35	<hr/>	
	Total	500 μ l

A solution containing SodB/CTXA2B chimeric protein was

prepared as described above.

Preparative Example 12: Solution containing UreI/CTXA2B
chimeric protein

5

UreI/CTXA2B chimeric protein	100 μ g
0.6M sodium bicarbonate	250 μ l
10 Distilled water	250 μ l
<hr/>	
Total	500 μ l

15 A solution containing UreI/CTXA2B chimeric protein was
prepared as described above.

Preparative Example 13: Solution containing UreE/CTXA2B
chimeric protein

20 UreE/CTXA2B chimeric protein	100 μ g
0.6M sodium bicarbonate	250 μ l
Distilled water	250 μ l
25	<hr/>
Total	500 μ l

A solution containing UreE/CTXA2B chimeric protein was
prepared as described above.

30

Preparative Example 14: Solution containing UreF/CTXA2B
chimeric protein

35 UreF/CTXA2B chimeric protein	100 μ g
0.6M sodium bicarbonate	250 μ l

Distilled water	250 μ l
<hr/>	
Total	500 μ l

- 5 A solution containing UreF/CTXA2B chimeric protein was prepared as described above.

Preparative Example 15: Solution containing UreG/CTXA2B chimeric protein

10

UreG/CTXA2B chimeric protein	100 μ g
0.6M sodium bicarbonate	250 μ l
15 Distilled water	250 μ l
<hr/>	
Total	500 μ l

- 20 A solution containing UreG/CTXA2B chimeric protein was prepared as described above.

Preparative Example 16: Solution containing UreH/CTXA2B chimeric protein

25 UreH/CTXA2B chimeric protein	100 μ g
0.6M sodium bicarbonate	250 μ l
Distilled water	250 μ l
30	<hr/>
Total	500 μ l

- A solution containing UreH/CTXA2B chimeric protein was prepared as described above.

35

Preparative Example 17: Solution containing FlaA/CTXA2B chimeric protein

	FlaA/CTXA2B chimeric protein	100 μ g
5	0.6M sodium bicarbonate	250 μ l
	Distilled water	250 μ l
	<hr/>	
	Total	500 μ l

10 A solution containing FlaA/CTXA2B chimeric protein was prepared as described above.

Preparative Example 18: Solution containing FlaB/CTXA2B chimeric protein

15	FlaB/CTXA2B chimeric protein	100 μ g
	0.6M sodium bicarbonate	250 μ l
20	Distilled water	250 μ l
	<hr/>	
	Total	500 μ l

25 A solution containing FlaB/CTXA2B chimeric protein was prepared as described above.

Preparative Example 19: Solution containing CatA/CTXA2B chimeric protein

30	CatA/CTXA2B chimeric protein	100 μ g
	0.6M sodium bicarbonate	250 μ l
	Distilled water	250 μ l
35	<hr/>	
	Total	500 μ l

A solution containing CatA/CTXA2B chimeric protein was prepared as described above.

Preparative Example 20: Solution containing VacA/CTXA2B chimeric protein

5

VacA/CTXA2B chimeric protein	100 μ g
0.6M sodium bicarbonate	250 μ l
Distilled water	250 μ l
<hr/>	
Total	500 μ l

10

15 A solution containing VacA/CTXA2B chimeric protein was prepared as described above.

Preparative Example 21: Solution containing BabB/CTXA2B chimeric protein

20

BabB/CTXA2B chimeric protein	100 μ g
0.6M sodium bicarbonate	250 μ l
Distilled water	250 μ l
<hr/>	
Total	500 μ l

25

30 A solution containing BabB/CTXA2B chimeric protein was prepared as described above.

As clearly illustrated and demonstrated as above, the present invention provides a series of recombinant DNAs which are prepared by ligating antigenic determinant coding genes of H. pylori and A2 and B subunit genes of Vibrio cholerae toxin, and a process for preparing the chimeric proteins of antigenic proteins of H. pylori and A2 and B subunits of Vibrio cholerae toxin, employing recombinant microorganisms

35

transformed with the recombinant expression vectors comprising the recombinant DNAs. The recombinant DNAs which are designed for convenient expression and gene manipulation, can express chimeric proteins having excellent immunogenicity to H. pylori, which are stable in stomach, and penetrate mucous membrane of intestines easily, finally to stimulate production of sIgA. Accordingly, the chimeric proteins expressed from the recombinant DNAs may be used as an active ingredient of the diagnostic kit for H. pylori infection and preventive or therapeutic vaccine for H. pylori-associated diseases, and may be used in the production of anti-H. pylori antibody.

15

20

25

30

35

WHAT IS CLAIMED IS:

1. A recombinant DNA comprising a fusion gene which is prepared by ligating antigenic determinant coding gene of Helicobacter pylori and A2 and B subunit genes of Vibrio cholerae toxin.

2. The recombinant DNA of claim 1, wherein the antigenic determinant coding gene of Helicobacter pylori is selected from the group consisting of ureB, cagA, alpA, alpB, fliQ, babA1, babA2, ureC, ureD, ureA, sodB, ureI, ureE, ureF, ureG, ureH, flaA, flaB, cataA, vacA and babB.

15

20

25

30

35

3. The recombinant DNA of claim 1, wherein the fusion gene which is prepared by ligating ureB gene of Helicobacter pylori and A2 and B subunit genes of Vibrio cholerae toxin, has a nucleotide sequence represented as following, or its functional equivalents:

```

1  atgaaaaaga ttagcagaaa agaatatgct tctatgtatg gccctactac aggcgataaa
10 61  gtgagattgg gcgatacaga cttgatcgct gaagtagaac atgactacac catttatggt
121 gaagagctta aattcggcgg cggtaaaacc ctaagagaag gcatgagcca atctaacaac
181 cctagcaaag aagaactigga tctaatacct actaacgctt taatcgtgga ttacaccggt
241 atttataaag cggatattgg tattaagat ggcaaaatcg ctggcattgg taaaggcggg
301 aacaaagaca cgcaagatgg cgtaaaaaac aatcttagcg tgggtcctgc tactgaagcc
361 ttagccgggtg aaggtttgat tgaactgct ggtggtattg acacacacat ccacttcac
15 421 tccccccaac aaatccctac agcttttgca agcgggtgta caaccatgat tgggtggcgga
481 actggccctg ctgatggcac taacgcaacc actatcactc caggtagaag aaatttaaaa
541 ttcattgctc gagcggctga agaataattt atgaactttg gtttcttggc taaaggtaac
601 gcttctaacg atgcaagctt agccgatcaa attgaagctg gtgcgattgg ccttaaaatc
661 cacgaagact ggggcaccac tccttctgca atcaatcatg cgttagatgt tgcggacaaa
721 tacgatgtgc aagtcgctat ccacacagac actttgaatg aagccggttg cgtggaagac
20 781 actatggcag ctattgccgg acgcactatg cacacttacc aactgaagg cgctggcggc
841 ggacacgctc ctgatattat taaagtggcc ggtgaacaca acatcctacc cgcttccact
901 aaccaccacta tccctttcac cgtgaatata gaagccgaac acatggacat gcttatgggtg
961 tgccaccact tggataaaag cattaaagaa gatgtccagt tcgctgattc aaggattcgc
1021 cctcaaacca ttgcggctga agacactttg catgacatgg ggattttctc aatcactagt
1081 tctgactctc aagcgatggg ccgtgtgggt gaagttatca ctagaacttg gcaaacagct
25 1141 gacaaaaata aaaaagaatt tggccgcttg aaagaagaaa aaggcgataa cgacaacttc
1201 aggatcaaac gctacttgct taaatacacc attaacccag cgatcgctca tgggattagc
1261 gagtatgtcg gttctgtaga agtgggcaaa gtggctgact tggatttggt gagtcccgca
1321 ttctttggtg tgaaacccaa catgatcatc aaaggcgggt tcatcgcatc gagtcaaatg
1381 ggtgatgcga acgcttctat ccctacccca caaccagttt attacagaga aatgttcgct
1441 catcatggta aagctaaata cgatgcaaac atcacttttg tgtctcaagc ggcttatgac
30 1501 aaaggcatta aagaagaatt agggcttgaa agacaagtgt tgccggtaaa aaattgcaga
1561 aatatcacta aaaaagacat gcaattcaac gacactaccg ctacattga agtcaattct
1621 gaaacttacc atgtgttcgt ggatggcaaa gaagtaactc taaaccagcc aataaagtga
1681 gaattcgaag agccgtggat tcatcatgca ccgccgggtt gtgggaatgc tccaagatca
1741 tcgatcagta atacttgca tgaaaaaacc caaagtctag gtgtaaaatt ccttgacgaa
1801 taccaatcta aagttaaaag acaaatattt tcaggctatc aatctgatat tgatacacat
35 1861 aatagaatta aggatgaatt aatgattaaa ttaaaatttg gtgttttttt tacagtttta
1921 ctatcttcag catatgcaca tggaacacct caaaatatta ctgatttggtg tgcagaatca
1981 cacaacacac aaatatatac gctaaatgat aagatatatt cgtatacaga atctctagct

```

2041 ggaaaaagag agatggctat cattactttt aagaatgggtg caatttttca agtagaagta
 5 2101 ccaagtagtc aacatataga ttcacaaaaa aaagcgattg aaaggatgaa ggataccctg
 2161 aggattgcat atcttactga agctaaagtc gaaaagttaa gtgtatggaa taataaaacg
 2221 cctcatgcga ttgccgaat tagtatggca aattaagata taaaaagccc acctcagtgg
 2281 gcttttttgt ggttcgatga tgagaagcaa ccgttttgcc caaacatgta ttactgcaag
 2385 tatgatgttt ttattccaca tccttagtgc gtattatgtg ctgca

10

4. The recombinant DNA of claim 1, wherein the fusion gene which is prepared by ligating cagA gene of Helicobacter pylori and A2 and B subunit genes of Vibrio cholerae toxin, has a nucleotide sequence represented as following, or its functional equivalents:

20 1 atgactaacg aaaccattga ccaacaacca caaaccgaag cggcttttaa cccgcagcaa
 61 tttatcaata atcttcaagt agcttttctt aaagttgata acgctgtcgc ttcatacgat
 121 cctgatcaaa aaccaatcgt tgataagaac gatagggata acaggcaagc ttttgaagga
 181 atctcgcaat taagggaaga atactccaat aaagcgatca aaaatcctac caaaaagaat
 241 cagtattttt cagactttat caataagagc aatgatttaa tcaacaaaga caatctcatt
 301 gatgtagaat cttccacaaa gagctttcag aaatttgggg atcagcgtaa ccgaattttc
 25 361 acaagttggg tgtcccatca aaacgatccg tctaaaaatca acacccgatc gatccgaaat
 421 tttatggaaa atatcataca accccctatc cttgatgata aagagaaagc ggagtttttg
 481 aaatctgcca aacaatcttt tgcaggaatc attataggga atcaaatccg aacggatcaa
 541 aagttcatgg gcgtgtttga tgagtccttg aaagaaaggc aagaagcaga aaaaaatgga
 601 gagcctactg gtggggattg gttggatatt tttctctcat ttatatttga caaaaaacaa
 661 tcttctgatg tcaaagaagc aatcaatcaa gaaccagttc cccatgtcca accagatata
 30 721 gccactacca ccaccgacat acaaggctta ccgcctgaag ctagagattt acttgatgaa
 781 aggggtaatt tttctaaatt cactcttggc gatatggaaa tgtagatgt tgagggagtc
 841 gctgacattg atcccaatta caagttcaat caattattga ttcacaataa cgctctgtct
 901 tctgtgttaa tggggagtca taatggcata gaacctgaaa aagtttcatt gttgtatggg
 961 ggcaatgggtg gtcctggagc taggcatgat tggaacgcca ccgttggtta taaagaccaa
 1021 caaggcaaca atgtggctac aataattaat gtgcatatga aaaacggcag tggcttagtc
 35 1081 atagcaggtg gtgagaaagg gattaacaac cctagttttt atctctacaa agaagaccaa
 1141 ctcacaggct cacaacgagc attaagtcaa gaagagatcc aaaacaaaat agatttcattg

5 1201 gaatttcttg cacaaaaataa tgctaaatta gataactiga gcgagaaaga gaaggaaaaa
1261 ttccgaactg agattaaaga ttccaaaaa gactctaagg cttatttaga cgccctaggg
1321 aatgatcgta ttgcttttgi ttctaaaaa gacacaaaac attcagcttt aattactgag
1381 tttggtaatg gggatttgag ctacactctc aaagattatg ggaaaaaagc agataaagct
1441 tiagataggg agaaaaatgt tactcttcaa ggtagcctaa aacatgatgg cgtgatgttt
1501 gttgattatt ctaatttcaa atacaccaac gcctccaaga atcccaataa gggtagggc
10 1561 gttacgaatg gcgtttccca tttagaagia ggctttaaca aggtagctat ctttaatttg
1621 cctgatttaa ataattctgc tatcactagt ttcgtaaggc ggaatttaga ggataaacta
1681 accactaaag gattgtcccc acaagaagct aataagctta tcaaagattt ttigagcagc
1741 aacaaagaat tgggtggaaa aactttaaac ttcaataaag ctgtagctga cgctaaaaac
1801 acaggcaatt atgatgaagt gaaaaaagct cagaaagatc ttgaaaaatc tctaaggaaa
1861 cgagagcatt tagagaaaga agtagagaaa aaattggaga gcaaaagcgg caacaaaaat
15 1921 aaaatggaag caaaagctca agctaacagc caaaaagatg agatttttgc gttgatcaat
1981 aaaggaggcta atagagacgc aagagcaatc gcttacgctc agaattctaa aggcatcaaa
2041 agggaaattgt ctgataaact tgaaaatgtc aacaagaatt tgaaagactt tgataaatct
2101 ttgatgaat tcaaaaatgg caaaaataag gatttcagca aggcagaaga aacactaaaa
2161 gcccttaaag gttcggtgaa agatttaggt atcaatccag aatggatttc aaaagttgaa
2221 aaccttaatg cagctttgaa tgaattcaaa aatggcaaaa ataaggattt cagcaaggta
20 2281 acgcaagcaa aaagcgacct tgaaaattcc gttaaagatg tgatcatcaa tcaaaaggta
2341 acggataaag ttgataatct caatcaagcg gtatcagtgg cttaaagcaac gggtagtttc
2401 agtagggtag agcaagcgtt agccgatctc aaaaatttct caaaggagca atiggcccaa
2461 caagctcaaa aaaatgaaag tcicaatgct agaaaaaaat ctgaaatata tcaatccgtt
2521 aagaatgggtg tgaatggaac cctagtcggt aatgggttat ctcaagcaga agccacaact
25 2581 ctttctaaaa acttttcgga catcaagaaa gatttgaatg caaaacttgg aaatttcaat
2641 aacaataaca ataattggact caaaaacgaa cccatttatg cttaaagtaa taaaaagaaa
2701 gcagggaag cagctagcct tgaagaaccc atttacgctc aagttgctaa aaaggtaa
2761 gcaaaaattg accgactcaa tcaaatagca agtgggttgg gtgttgtagg gcaagcagcg
2821 ggcttccctt tgaaaaggca tgataaagtt gatgatctca gtaaggtagg gctttcaagg
30 2881 aatcaagaat tggctcagaa aattgacaat ctcaatcaag cggatcaga agctaaagca
2941 ggtttttttg gcaatctaga gcaaacgata gacaagctca aagattctac aaaacacaat
3001 cccatgaatc tatgggttga aagtgcacaa aaagtacctg ctagttgtc agcgaaacta
3061 gacaattacg ctactaacag ccacatacgc attaatagca atatcaaaaa tggagcaatc
3121 aatgaaaaag cgaccggcat gctaacgcaa aaaaacctg agtggctcaa gctcgtgaat
35 3181 gataagatag ttgcgcataa tgtaggaagc gtccctttgt cagagtatga taaaattggc
3241 ttcaaccaga agaatatgaa agattattct gattcgtica agttttccac caagttgaac
3301 aatgctgtaa aagacactaa ttctggcttt acgcaatttt taaccaatgc attttctaca

5 3361 gcatcttatt actgcttggc gagagaaaat gcggagcatg gaatcaagaa cgtaaataca
3421 aaagggtggtt tccaaaaatc ttaagaattc gaagagccgt ggattcatca tgcaccgccg
3481 ggttgtggga atgctccaag atcatcgatc agtaatactt gcgatgaaaa aacccaaagt
3541 ctaggtgtaa aattccttga cgaataccaa tctaaagtta aaagacaaat attttcaggc
3601 tatcaatctg atattgatac acataataga attaaggatg aattaatgat taaattaaaa
10 3661 ttigggtgtt tttttacagt tt tactatct tcagcatatg cacatggaac acctcaaaat
3721 attactgatt tgtgtgcaga atcacacaac acacaaatat atacgctaaa tgataagata
3781 ttttcgtata cagaatctct agctggaaaa agagagatgg ctatcattac ttttaagaat
3841 ggtgcaattt ttcaagtaga agtaccaagt agtcaacata tagattcaca aaaaaaagcg
3901 attgaaagga tgaaggatac cctgaggatt gcataatctta ctgaagctaa agtcgaaaag
15 3961 ttatgtgtat ggaataataa aacgcctcat gcgattgccg caattagtat ggcaaattaa
4021 gatataaaaa gcccacctca gtgggctttt ttgtggttcg atgatgagaa gcaaccgttt
4081 tgcccaaaca tgtattactg caagtatgat gtttttattc cacatcctta gtgcgtatta
4154 tgtgctgca

20

25

30

35

5. A chimeric protein consisting of antigenic protein of Helicobacter pylori and A2 and B subunits of Vibrio cholerae toxin which has an amino acid sequence deducible
5 from the recombinant DNA of claim 1, or its functional equivalents.

6. The chimeric protein of claim 5, wherein the antigenic protein of Helicobacter pylori is selected from the group
10 consisting of UreB, CagA, AlpA, AlpB, FliQ, BabA1, BabA2, UreC, UreD, UreA, SodB, UreI, UreE, UreF, UreG, UreH, FlaA, FlaB, CatA, VacA and BabB.

15

20

25

30

35

7. A chimeric protein which is prepared by ligating UreB of Helicobacter pylori and A2 and B subunits of Vibrio cholerae toxin, has an amino acid sequence represented as following, or its functional equivalents:

1 MKISRKEYA SMYGPTTGDK VRLGDTDLIA EVEHDYTIYG EELKFGGGKT LREGMSQSNN
61 PSKEELDLII TNALIVDYTG IYKADIGIKD GKIAGIGKGG NKDTQDGVKN NLSVGPATEA
10 121 LAGEGLIVTA GGIDTHIHF1 SPQQIPTAFA SGVTTMIGGG TGPADGTNAT TITPGRRLNK
181 FNLRAAEEYS MNFGFLAKGN ASNDASLADQ IEAGAIGLKI HEDWGTTPSA INHALDVADK
241 YDVQVAIHTD TLNEAGCVED TMAAIAGRTM HTYHTEGAGG GHAPDIKVA GEHNILPAST
301 NPTIPFTVNT EAEHMDMLMV CHHLDKSIKE DVQFADSRIR POTIAAEDTL HDMGIFSITS
361 SDSQAMGRVG EVITRTWQTA DKNKKEFGRL KEEKGDNDNF RIKRYLSKYT INPAIAHGIS
15 421 EYVGSVEVGK VADLVLWSPA FFGVKPNMII KGGFIALSQM GDANASIPTP QPVYYREMFA
481 HHGKAKYDAN ITFVSQAAYD KGIKEELGLE RQVLPVKNCR NITKKDMQFN DTTAHIEVNS
541 ETYHVFVDGK EVTLNQPIKE FEETWIIHAP PGCGNAPRSS ISNTCDEKTO SLGVKFLDEY
601 QSKVKRQIFS GYQSDIDTHN RIKDELMIKL KFGVFFTVLL SSAYAHGTPQ NITDLCAESH
661 NTQIYTLNDK IFSYTESLAG KREMAIITFK NGAIFQVEVP SSQHIDSQKK AIERNKDTLR
20 750 IAYLTEAKVE KLCVWNNKTP HAIAAISMAN

25

30

35

8. A chimeric protein which is prepared by ligating CagA of Helicobacter pylori and A2 and B subunits of Vibrio cholerae toxin, has an amino acid sequence represented as following, or its functional equivalents:

```

1 MTNETIDQQP QTEAAFNPQQ FINNLQVAFI KVDNAVASYD PDQKPIVDKN DRDNRQAFEG
10 61 ISQLREEYSN KAIKNPTKKK QYFSDFINKS NDLINKDNLI DVESSTKSFQ KFGDQRYRIF
121 TSWVSHQNDP SKINTRSIRN FMENIIQPPI LDDKEKAEFL KSAKQSFAGI IIGNQIRTDQ
181 KFMGVFDESL KERQEA EKNG EPTGGDWLDI FLSFIFDKKQ SSDVKEAINQ EPVPHVQPD
241 ATTTTIDIQGL PPEARDLLDE RGNFSKFTLG DMEMLDVEGV ADIDPNYKFN QLLIHNNAIS
301 SVLMGSHNGI EPEKVSLLYG GNGGPGARHD WNATVGKDKQ QGNNVATIIN VHMKNKSGLV
15 361 IAGGEKGINN PSFYLYKEDQ LTGSQRALSQ EEIQNKIDFM EFLAQNNAKL DNLSEKEKEK
421 FRTEIKDFQK DSKAYLDALG NDRIAFVSKK DTKHSALITE FGNGDLSYTL KDYGKKADKA
481 LDREKNVTIQ GSLKHDGVMF VDYSNFKYTN ASKNPNKGVG VTNGVSHLEV GFNKVAIFNL
541 PDLNNLAITS FVRRNLEDKL TTKGLSPQEA NKLIKDFLSS NKELVGKTLN FNKAVADAKN
601 TGNIDEVKKK QKDLEKSLRK REHLEKEVEK KLESKSGNKN KMEAKAQANS QKDEIFALIN
20 661 KEANRDARAI AYAQNKGKIK RELSDKLENV NKNLKDFFDKS FDEFKNGKNK DFSKAEETLK
721 ALKGSVKDLG INPEWISKVE NLNAALNEFK NGKNKDFSKV TQAKSDLENS VKDVIINQKV
781 TDKVDNLNQA VSVAKATGDF SRVEQALADL KNFSKEQLAQ QAQKNESLNA RKKSEIYQSV
841 KNGVNGTLVG NGLSQAEATT LSKNFSDIKK ELNAKLGNFN NNNNGLKNE PIYAKVNKKK
901 AGQAASLEEP IYAQVAKKVN AKIDRLNQIA SGLGVVGQAA GFPLKRHDKV DDLSKVGLSR
25 961 NQELAQKIDN LNQAVSEAKA GFFGNLEQTI DKLKDSTKHN PMNLWVESAK KVPASLSAKL
1021 DNYATNSHIR INSNKNGAI NEKATGMLTQ KNPEWLKLVN DKIVAHNVGS VPLSEYDKIG
1081 FNQKNMKDYS DSFKFSTKLN NAVKDTNSGF TQFLTNAFST ASYYCLAREN AEHGIKNVNT
1141 KGGFQKSEFE EPWIIHAPPG CGNAPRSSIS NTCDEKTQSL GVKFLDEYQS KVKRQIFSGY
1201 QSDIDTHNRI KDELMIKLKF GVFFTVLLSS AYAHGTPQNI TDLCAESHNT QIYTLNDKIF
30 1261 SYTESLAGKR EMAIITFKNG AIFQVEVPSS QHIDSQKKAI ERMKDTLRIA YLTEAKVEKL
1338 CVWNNKTPHA IAAISMAN


```

9. A recombinant expression vector which comprises the recombinant DNA of claim 1, to express a chimeric protein consisting of antigenic protein of Helicobacter pylori and A2 and B subunits of Vibrio cholerae toxin.

10. A recombinant expression vector which is capable of expressing a chimeric protein consisting of UreB of Helicobacter pylori and A2 and B subunits of Vibrio cholerae toxin, represented as following genetic map:

15


20



11. A recombinant expression vector which is capable of expressing a chimeric protein consisting of CagA of Helicobacter pylori and A2 and B subunits of Vibrio cholerae toxin, represented as following genetic map:

30

35



12. A recombinant Escherichia coli transformed with the recombinant expression vector of claim 9.

13. Escherichia coli DW/HU-044 (KCCM-10124) which is capable of expressing a chimeric protein consisting of UreB of Helicobacter pylori and A2 and B subunits of Vibrio cholerae toxin.

14. Escherichia coli DW/HC-033 (KCCM-10123) which is capable of expressing a chimeric protein consisting of CagA of Helicobacter pylori and A2 and B subunits of Vibrio cholerae toxin.

15. A process for preparing a chimeric protein which comprises the steps of: culturing a microorganism transformed with the recombinant expression vector of claim 9; and, recovering a chimeric protein consisting of antigenic protein of Helicobacter pylori and A2 and B subunits of Vibrio cholerae toxin.

16. The process for preparing a chimeric protein of claim 15, wherein the antigenic protein of Helicobacter pylori is selected from the group consisting of UreB, CagA, AlpA, AlpB, FlhQ, BabA1, BabA2, UreC, UreD, UreA, SodB, UreI, UreE, UreF, UreG, UreH, FlaA, FlaB, CatA, VacA and BabB.

17. The process for preparing a chimeric protein of claim 15, wherein the microorganism is Escherichia coli DW/HU-044 (KCCM-10124).

18. The process for preparing a chimeric protein of claim 15, wherein the microorganism is Escherichia coli DW/HC-033 (KCCM-10123).

19. A chimeric protein which is prepared by the process comprising the steps of: culturing a microorganism transformed with the recombinant expression vector of claim

recombinant expression vector of claim 9; and, recovering a chimeric protein consisting of antigenic protein of Helicobacter pylori and A2 and B subunits of Vibrio cholerae toxin.

5

20. The chimeric protein of claim 19, wherein the antigenic protein of Helicobacter pylori is selected from the group consisting of UreB, CagA, AlpA, AlpB, FliQ, BabA1, BabA2, UreC, UreD, UreA, SodB, UreI, UreE, UreF, UreG, UreH,
10 FlaA, FlaB, CatA, VacA and BabB.

21. A preventive and therapeutic vaccine for Helicobacter pylori-associated diseases which comprises an active ingredient of a chimeric protein consisting of
15 antigenic protein of Helicobacter pylori and A2 and B subunits of Vibrio cholerae toxin, and its pharmaceutically acceptable carrier.

22. The preventive and therapeutic vaccine for
20 Helicobacter pylori-associated diseases of claim 21, wherein the antigenic protein of Helicobacter pylori is selected from the group consisting of UreB, CagA, AlpA, AlpB, FliQ, BabA1, BabA2, UreC, UreD, UreA, SodB, UreI, UreE, UreF, UreG, UreH, FlaA, FlaB, CatA, VacA and BabB.

25

23. The preventive and therapeutic vaccine for Helicobacter pylori-associated diseases of claim 21, wherein the Helicobacter pylori-associated diseases comprise gastritis, gastric ulcer, duodenal ulcer and gastric cancer.
30

35

1/10

1 atgaaaaaga ttagcagaaa agaatatgct tctatgtatg gccctactac aggcgataaa
61 gtgagattgg gcgatacaga ctigatcgct gaagtagaac atgactacac catttatggt
121 gaagagctta aaticggcgg cggtaaaacc ctaagagaag gcatgagcca atctaacaac
181 cctagcaaag aagaactgga tctaatacct actaacgctt taatcgtgga ttacaccggt
241 atttataaag cgcatattgg tattaagat ggcaaaatcg ctggcattgg taaaggcggt
301 aacaaagaca cgcaagatgg cggtaaaaac aatcttagcg tgggtcctgc tactgaagcc
361 ttagccgggtg aaggtttgat tgtaactgct ggtgggtattg acacacacat ccacttcac
421 tcccccaac aaatccctac agcttttgca agcgggtgta caaccatgat tgggtggcgga
481 actggccctg ctgatggcac taacgcaacc actatcactc caggtagaag aaatttaaaa
541 ttcattgctca gagcggctga agaataattt atgaactttg gtttcttggc taaaggtaac
601 gcttctaacg atgcaagctt agccgatcaa attgaagctg gtgcgattgg ctttaaaatc
661 cacgaagact ggggcaccac tccttctgca atcaatcatg cgttagatgt tgcggacaaa
721 tacgatgtgc aagtcgctat ccacacagac actttgaatg aagccggttg cgtggaagac
781 actatggcag ctattgccgg acgcactatg cacacttacc aactgaagg cgctggcggc
841 ggacacgctc ctgatattat taaagtggcc ggtgaacaca acatcctacc cgcttccact
901 aaccccacta tccctttcac cgtgaatata gaagccgaac acatggacat gcttatgggt
961 tgccaccact tggataaaag cattaaagaa gatgtccagt tcgctgattc aaggattcgc
1021 cctcaaacca ttgcccgtga agacactttg catgacatgg ggattttctc aatcactagt
1081 tctgactctc aagcgatggg ccgtgtgggt gaagttatca ctagaacttg gcaaacagct
1141 gacaaaaata aaaaagaatt tggccgcttg aaagaagaaa aaggcgataa cgacaacttc
1201 aggatcaaac gctacttgct taaatacacc attaaccag cgatcgctca tgggattagc
1261 gagtatgtcg gttctgtaga agtgggcaaa gtggctgact tggatttggt gagtcccgca
1321 ttctttgggt tgaaaccaa catgatcact aaaggcgggt tcatcgcat gagtcaaatg
1381 ggtgatgcga acgcttctat ccctacccca caaccagttt attacagaga aatgttcgct
1441 catcatggta aagctaaata cgatgcaaac atcacttttg tgtctcaagc ggcttatgac
1501 aaaggcatta aagaagaatt agggcttgaa agacaagtgt tgccggtaaa aaattgcaga
1561 aatatcacta aaaaagacat gcaattcaac gacactaccg ctacattga agtcaattct
1621 gaaacttacc atgtgttcgt ggatggcaaa gaagtaactc taaaccagcc aataaagtga
1681 gaattcgaag agccgtggat tcatcatgca ccgccgggtt gtgggaatgc tccaagatca
1741 tcgatcagta atacttgca tgaaaaaacc caaagtctag gtgtaaaatt ccttgacgaa
1801 taccaatcta aagttaaaag acaaatattt tcaggctatc aatctgatat tgatacacat
1861 aatagaatta aggatgaatt aatgattaaa taaaatttg gtgtttttt tacagtitta
1921 ctatcttcag catatgcaca tggaacacct caaaatatta ctgatttggt tgcagaatca
1981 cacaacacac aaatatatac gctaaatgat aagatatttt cgtatacaga atctctagct
2041 ggaaaaagag agatggctat cattactttt aagaatgggt caatttttca agtagaagta
2101 ccaagtagtc aacatataga ttcacaaaaa aaagcgattg aaaggatgaa ggataccctg
2161 aggattgcat atcttactga agctaaagtc gaaaagtatt gtgtatggaa taataaaacg
2221 cctcatgcga ttgccgcaat tagtatggca aattaagata taaaagccc acctcagtg
2281 gcttttttgt ggttcgatga tgagaagcaa ccgttttgcc caaacatgta ttactgcaag
2385 tatgatgttt ttattccaca tccttagtgc gtattatgtg ctgca

Fig. 1

2/10

1 MKISRKEYA SMYGPTTGDK VRLGDTDLIA EVEHDYTIYG EELKFGGGKT LREGMSQSNN
61 PSKEELDLII TNALIVDYTG IYKADIGIKD GKIAGIGKGG NKDTQDGVKN NLSVGPATEA
121 LAGEGLIVTA GGIDTHIHF I SPQQIPTAFA SGVTTMIGGG TGPADGTNAT TITPGRRLNK
181 FMLRAAEEYS MNFGFLAKGN ASNDASLADQ IEAGAIGLKI HEDWGTTPSA INHALDVADK
241 YDVQVAIHTD TLNEAGCVED TMAAIAGRTM HTYHTEGAGG GHAPDIKVA GEHNILPAST
301 NPTIPFTVNT EAEHMDMLMV CHHLDKSIKE DVQFADSRIR PQTIAAEDTL HDMGIFSITS
361 SDSQAMGRVG EVITRTWQTA DKNKKEFGRL KEEKGDNDNF RIKRYLSKYT INPAIAHGIS
421 EYVGSVEVGK VADLVWSPA FFGVKPNMII KGGFIALSQM GDANASIPTP QPVYYREMFA
481 HHGKAKYDAN ITFVSQAAYD KGIKEELGLE RQVLPVKNCR NITKKDMQFN DTTAHIEVNS
541 ETYHVFVDGK EVTLNQPIKE FEPPWIHHAP PGCGNAPRSS ISNTCDEKTQ SLGVKFLDEY
601 QSKVKRQIFS GYQSDIDTHN RIKDELMIKL KFGVFFTVLL SSAYAHGTPQ NITDLCAESH
661 NTQIYTLNDK IFSYTESLAG KREMAIITFK NGAIQVEVP SSQHIDSQKK AIERMKDTLR
750 IAYLTEAKVE KLCVWNNKTP HAIAAISMAN

Fig. 2

3/10

1 atgactaacg aaaccattga ccaacaacca caaaccgaag cggcttttaa cccgcagcaa
61 tttatcaata atcttcaagt agcttttctt aaagttgata acgctgtcgc ttcatacgat
121 cctgatcaaa aaccaatcgt tgataagaac gatagggata acaggcaagc ttttgaagga
181 atctcgcaat taagggaaga atactccaat aaagcgatca aaaatcctac caaaaagaat
241 cagtattttt cagactttat caataagagc aatgatttaa tcaacaaaga caatctcatt
301 gatgtagaat ctccacaaa gagctttcag aaatttgggg atcagcgta ccgaattttc
361 acaagttggg tgtcccatca aaacgatccg tctaaaatca acacccgatc gatccgaaat
421 tttatggaaa atatcataca accccctatc cttgatgata aagagaaagc ggagtttttg
481 aaatctgcca aacaatcttt tgcaggaatc attataggga atcaaaccg aacggatcaa
541 aagttcatgg gcgtgtttga tgagtccttg aaagaaaggc aagaagcaga aaaaaatgga
601 gagcctactg gtggggattg gttggatatt tttctctcat ttatatttga caaaaaacaa
661 tcttctgatg tcaaagaagc aatcaatcaa gaaccagttc cccatgtcca accagatata
721 gccactacca ccaccgacat acaaggctta ccgcctgaag ctagagattt acttgatgaa
781 aggggtaatt tttctaaatt cactcttggc gatattggaaa tgtagatgt tgaggggagtc
841 gctgacattg atcccaatta caagttcaat caattattga ttcacaataa cgctctgtct
901 tctgtgttaa tggggagtca taatggcata gaacctgaaa aagtttcatt gttgtatggg
961 ggcaatgggtg gtcctggagc taggcattgat tggaacgcca ccgttggta taaagaccaa
1021 caaggcaaca atgtggctac aataattaat gtgcatatga aaaacggcag tggcttagtc
1081 atagcagggtg gtgagaaagg gattaacaac cctagttttt atctctacaa agaagaccaa
1141 ctacacaggct cacaacgagc attaatgcaa gaagagatcc aaaacaaaat agatttcattg
1201 gaatttcttg cacaaaataa tgctaaatta gacaacttga gcgagaaaaga gaaggaaaaa
1261 ttccgaactg agattaaaga tttccaaaaa gactctaagg cttattttaga cgccctaggg
1321 aatgatcgta ttgcttttgt ttctaaaaaa gacacaaaac attcagcttt aattactgag
1381 tttggtaatg gggatttgag ctacactctc aaagattatg ggaaaaaagc agataaagct
1441 ttagataggg agaaaaatgt tactcttcaa ggtagcctaa aacatgatgg cgtgatgttt
1501 gttgattatt ctaatttcaa atacaccaac gcctccaaga atcccaataa ggggttaggc
1561 gttacgaatg gcgtttcca tttagaagta ggctttaaca aggtagctat ctttaatttg
1621 cctgatttaa ataatctcgc tatcactagt ttcgtaaggc ggaattttaga ggataaacta
1681 accactaaag gattgtcccc acaagaagct aataagctta tcaaagattt tttagcagc
1741 aacaaagaat tggttggaaa aactttaaac ttcaataaag ctgtagctga cgctaaaaac
1801 acaggcaatt atgatgaagt gaaaaaagct cagaaagatc ttgaaaaatc tctaaggaaa
1861 cgagagcatt tagagaaaga agtagagaaa aaattggaga gcaaaagcgg caacaaaaat
1921 aaaatggaag caaaagctca agctaacagc caaaaagatg agatttttgc gttgatcaat
1981 aaagaggcta atagagacgc aagagcaatc gcttacgctc agaattctaa aggcattcaa
2041 aggggaattgt ctgataaact tgaaaatgtc aacaagaatt tgaaagactt tgataaatct
2101 tttgatgaat tcaaaaatgg caaaaataag gatttcagca aggcagaaga aacactaaaa
2161 gcccttaaag gttcgggtgaa agatttaggt atcaatccag aatggatttc aaaagttgaa
2221 aaccttaatg cagctttgaa tgaattcaaa aatggcaaaa ataaggattt cagcaaggta

Fig. 3

2281 acgcaagcaa aaagcgacct tgaaaattcc gttaaagatg tgatcatcaa tcaaaaggta
2341 acggataaag ttgataatct caatcaagcg gtatcagtgg ctaaagcaac ggggtgatttc
2401 agtagggtag agcaagcgtt agccgatctc aaaaatttct caaaggagca attggcccaa
2461 caagctcaaa aaaaatgaaag tctcaatgct agaaaaaat ctgaaatata tcaatccgtt
2521 aagaatgggtg tgaatggaac cctagtcggt aatgggttat ctcaagcaga agccacaact
2581 ctttctaaaa acttttcgga catcaagaaa gagttgaatg caaaacttgg aaatttcaat
2641 aacaataaca ataatggact caaaaacgaa cccatttatg ctaaagttaa taaaaagaaa
2701 gcagggcaag cagctagcct tgaagaaccc atttacgctc aagttgctaa aaaggtaaat
2761 gcaaaaattg accgactcaa tcaaatagca agtgggttgg gtgtttagg gcaagcagcg
2821 ggcttccctt tgaaaaggca tgataaagtt gatgatctca gtaaggtagg gctttcaagg
2881 aatcaagaat tggctcagaa aattgacaat ctcaatcaag cggatcaga agctaaagca
2941 ggtttttttg gcaatctaga gcaaacgata gacaagctca aagattctac aaaacacaat
3001 cccatgaatc tatgggttga aagtgcacaaa aaagtacctg ctagtttgctc agcgaaacta
3061 gacaattacg ctactaacag ccacatacgc attaatagca atatcaaaaa tggagcaatc
3121 aatgaaaaag cgaccggcat gctaacgcaa aaaaaccctg agtggctcaa gctcgtgaat
3181 gataagatag ttgcgcataa tgtaggaagc gttcctttgt cagagtatga taaaattggc
3241 ttcaaccaga agaatatgaa agattattct gattcgttca agttttccac caagttgaac
3301 aatgctgtaa aagacactaa ttctggcttt acgcaatttt taaccaatgc attttctaca
3361 gcatcttatt actgcttggc gagagaaaaat gcggagcatg gaatcaagaa cgtaataca
3421 aaagggtggtt tccaaaaatc ttaagaattc gaagagccgt ggattcatca tgcaccgccg
3481 ggttgtggga atgctccaag atcatcgatc agtaatactt gcgatgaaaa aacccaaagt
3541 ctaggtgtaa aattccttga cgaataccaa tctaaagtta aaagacaaat attttcaggc
3601 tatcaatctg atattgatac acataataga attaaggatg aattaatgat taaattaaaa
3661 tttggtgttt tttttacagt ttactatct tcagcatatg cacatggaac acctcaaaat
3721 attactgatt tgtgtgcaga atcacacaac acacaaatat atacgctaaa tgataagata
3781 ttttcgtata cagaatctct agctggaaaa agagagatgg ctatcattac ttttaagaat
3841 ggtgcaattt ttcaagtaga agtaccaagt agtcaacata tagattcaca aaaaaaagcg
3901 attgaaagga tgaaggatac cctgaggatt gcatacttta ctgaagctaa agtcgaaaag
3961 ttatgtgtat ggaataataa aacgcctcat gcgattgccg caattagtat ggcaaattaa
4021 gatataaaaa gcccacctca gtgggctttt ttgtggttcg atgatgagaa gcaaccgttt
4081 tgcccaaaca tgtattactg caagtatgat gtttttattc cacatcctta gtgcgtatta
4154 tgtgctgca

Fig. 3 (continued)

5/10

1 MTNETIDQQP QTEAAFNPQQ FINNLQVAFI KVDNAVASYD PDQKPIVDKN DRDNRQAFEG
61 ISQLREEYSN KAIKNPTKKN QYFSDFINKS NDLINKDNLI DVESSTKSFQ KFGDQRYRIF
121 TSWVSHQNDP SKINTRSIRN FMENIIQPPI LDDKEKAEFL KSAKQSFAGI IIGNQIRTDQ
181 KFMGVFDESL KERQAEKNG EPTGGDWLDI FLSFIFDKKQ SSDVKEAINQ EPVPHVQPD
241 ATTTTIDIQGL PPEARDLLDE RGNFSKFTLG DMEMLDVEGV ADIDPNYKFN QLLIHNNALS
301 SVLMGSHNGI EPEKVSLLYG GNGGPGARHD WNATVGYKDQ QGNNVATIIN VHMKNNGSLV
361 IAGGEKGINN PSFYLYKEDQ LTGSQRALSQ EEIQNKIDFM EFLAQNNAKL DNLSEKEKEK
421 FRTEIKDFQK DSKAYLDALG NDRIAFVSKK DTKHSALITE FGNGDLSYTL KDYGKKADKA
481 LDREKNVTIQL GSLKHDGVMF VDYSNFKYTN ASKNPNKGVG VTNGVSHLEV GFNKVAIFNL
541 PDLNNLAITS FVRRNLEDKL TTKGLSPQEA NKLIKDFLSS NKELVGKTLN FNKAVADAKN
601 TGNVDEVKKA QKDLEKSLRK REHLEKEVEK KLESKSGNKN KMEAKAQANS QKDEIFALIN
661 KEANRDARAI AYAQNLKGIK RELSDKLENV NKNLKDFFKS FDEFKNGKNK DFSKAEETLK
721 ALKGSVKDLG INPEWISKVE NLNAALNEFK NGKNKDFSKV TQAKSDLENS VKDVIINQKV
781 TDKVDNLNQA VSVAKATGDF SRVEQALADL KNFSKEQLAQ QAQKNESLNA RKKSEIYQSV
841 KNGVNGTLVG NGLSQAEATT LSKNFSDIKK ELNAKLGNFN NNNNGLKNE PIYAKVNKKK
901 AGQAASLEEP IYAQVAKKVN AKIDRLNQIA SGLGVVQAA GFPLKRHDKV DDLSKVGLSR
961 NQELAQKIDN LNQAVSEAKA GFFGNLEQTI DKLKDSTKHN PMNLWVESAK KVPASLSAKL
1021 DNYATNSHIR INSNIKNGAI NEKATGMLTQ KNPEWLKLVN DKIVAHNVGS VPLSEYDKIG
1081 FNQKNMKDYS DSFKFSTKLN NAVKDTNSGF TQFLTNAFST ASYYCLAREN AEHGIKNVNT
1141 KGGFQKSEFE EPWIIHAPPG CGNAPRSSIS NTCDEKTQSL GVKFLDEYQS KVKRQIFSGY
1201 QSDIDTHNRI KDELMIKLF GVFFTLLSS AYAHTGPQNI TDLCAESHNT QIYTLNDKIF
1261 SYTESLAGKR EMAIITFKNG AIFQVEVPSS QHIDSQKKAI ERMKDTLRIA YLTEAKVEKL
1338 CVWNNKTPHA IAAISMAN

Fig. 4

6/10




Fig. 5

7/10




Fig. 6

8/10




Fig. 7




Fig. 8

9/10




Fig. 9




Fig. 10

10/10




Fig. 11




Fig. 12

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

To. Daewoong Pharmaceutical Co. LTD.

223-23 Sangdaewon-Dong,
Jungwon-Ku, Sungnam, Kyungi-Do
462-120,
Republic of Korea

RECEIPT IN THE CASE OF AN ORIGINAL
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR : <i>Escherichia coli</i> DW/HU-044	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY : KCCM - 10124
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by: <input type="checkbox"/> a scientific description <input type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
the microorganism identified under I above was received by this international Depositary Authority on Mar. 12, 1997 and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on Mar. 1, 1998.	
IV. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Korean Culture Center of Microorganisms Address: Department of Food Engineering College of Eng. Yonsei University Sodaemun-gu, Seoul 120-749 Korea	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s) : Date: Mar. 2, 1998

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

To. Daewoong Pharmaceutical Co. LTD.

223-23 Sangdaewon-Dong,
Jungwon-Ku, Sungnam, Kyungi-Do
462-120,
Republic of Korea

RECEIPT IN THE CASE OF AN ORIGINAL
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR : <i>Escherichia coli</i> DW/HU-044	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY : KCCM - 10124
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by: <input type="checkbox"/> a scientific description <input type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
the microorganism identified under I above was received by this international Depositary Authority on Mar. 12, 1997 and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on Mar. 1, 1998.	
IV. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Korean Culture Center of Microorganisms Address: Department of Food Engineering College of Eng. Yonsei University Sodaemun-gu, Seoul 120-749 Korea	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s) : Date: Mar. 2, 1998

INTERNATIONAL SEARCH REPORT

International application No.

P KR 98/00073

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁶: C 12 N 15/62, 1/21; A 61 K 39/02 // (C 12 N 1/21; C 12 R 1:19; C 12 N 15/62;
According to International Patent Classification (IPC) or to both national classification and IPC C 12 R 1:63)

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁶: C 12 N 15/62, 1/21; A 61 K 39/02

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97/11 182 A1 (MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.) 27 March 1997 (27.03.97), abstract; claim 15. -----	1,15,21,23

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

09 June 1998 (09.06.98)

Date of mailing of the international search report

30 June 1998 (30.06.98)

Name and mailing address of the ISA/ AT
AUSTRIAN PATENT OFFICE
Kohlmarkt 8-10
A-1014 Vienna
Facsimile No. 1/53424/535

Authorized officer

Wolf

Telephone No. 1/53424/436

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
/KR 98/00073

In Recherchenbericht angeführtes Patentedokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
WO A1 9711182	27-03-97	AU A1 71314/96 DE A1 19535321	09-04-97 27-03-97